1
|
Brock P, Meijer A, Kogner P, Ansari M, Capra M, Geller J, Heuvel-Eibrink MVD, Knight K, Kruger M, Lindemulder S, Maibach R, O'Neill A, Papadakis V, Rajput K, Bleyer A, Bouffet E, Sullivan M. Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it. Pediatr Blood Cancer 2023; 70:e30248. [PMID: 36772889 DOI: 10.1002/pbc.30248] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 01/20/2023] [Indexed: 02/12/2023]
Affiliation(s)
- Penelope Brock
- Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Annelot Meijer
- Department of Pediatric Oncology, Prinses Maxima Centrum, Utrecht, The Netherlands
| | - Per Kogner
- Department of Pediatric Oncology and Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden
| | - Marc Ansari
- Pediatric Hematology and Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Michael Capra
- Paediatric Oncology, Our Lady's Children's Hospital, Dublin, Ireland
| | - James Geller
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | | | - Kristin Knight
- Department of Pediatric Audiology, Oregon Health and Science University, Portland, Oregon, USA
| | - Mariana Kruger
- Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa
| | - Susan Lindemulder
- Department of Pediatric Oncology, Oregon Health and Science University, Portland, Oregon, USA
| | - Rudolf Maibach
- Department of Statistics, International Breast Cancer Study Group, Bern, Switzerland
| | - Allison O'Neill
- Children's Cancer and Blood Disorders Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Vassilios Papadakis
- Department of Pediatric Oncology, Agia Sofia Children's Hospital, Athens, Greece
| | - Kaukab Rajput
- Department of Paediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Archie Bleyer
- Radiation Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
| | - Eric Bouffet
- Division of Pediatric Neuro-Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michael Sullivan
- Children's Cancer Centre and Department of Paediatric Oncology, Royal Children's Hospital, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Menegotto PR, Soares T, Santin A, Eckert D, Hackner I, Fassina K, Morsch KT, Lindenmeyer L, Capra M. EXPERIÊNCIA DE UM SERVIÇO PÚBLICO DE PORTO ALEGRE-RS COM OS PRIMEIROS PACIENTES SUBMETIDOS AO TRANSPLANTE DE CÉLULAS TRONCO HEMATOPOIÉTICAS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
3
|
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Abdulrahaman AA, Abouelnaga S, Ademola-Popoola DS, Adio A, Afifi MA, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Akinsete A, Al Harby L, Al Mesfer S, Al Ani MH, Alarcón Portabella S, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad CE, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amankwaa-Frempong D, Amiruddin PO, Armytasari I, Astbury NJ, Atalay HT, Ataseven E, Atchaneeyasakul LO, Atsiaya R, Autrata R, Balaguer J, Balayeva R, Barranco H, Bartoszek P, Bartuma K, Bascaran C, Bechrakis NE, Beck Popovic M, Begimkulova AS, Benmiloud S, Berete RC, Berry JL, Bhaduri A, Bhat S, Bhattacharyya A, Biewald EM, Binkley E, Blum S, Bobrova N, Boldt H, Bonanomi MTBC, Bouda GC, Bouguila H, Brennan RC, Brichard BG, Buaboonnam J, Budiongo A, Burton MJ, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Caspi S, Cassoux N, Castela G, Castillo L, Català-Mora J, Cavieres I, Chandramohan A, Chantada GL, Chaudhry S, Chawla B, Chen W, Chiwanga FS, Chuluunbat T, Cieslik K, Clark A, Cockcroft RL, Comsa C, Correa Llano MG, Corson TW, Couitchere L, Cowan-Lyn KE, Csóka M, Dangboon W, Das A, Das P, Das S, Davanzo JM, Davidson A, De Francesco S, De Potter P, Quintero D K, Demirci H, Desjardins L, Díaz Coronado RY, Dimaras H, Dodgshun AJ, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Du Plessis J, Dudeja G, Eerme K, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elhaddad AM, Elhassan MMA, Elzembely MM, Ericksen C, Essuman VA, Evina TGA, Ezegwui IR, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Garcia JL, García Aldana D, Garcia Pacheco HN, Geel JA, Ghassemi F, Girón AV, Goenz MA, Gold AS, Goldberg H, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Gorfine M, Graells J, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Gupta V, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Muhammad H, Hassan S, Hassan S, Hautz W, Haydar H, Hederova S, Hessissen L, Hongeng S, Hordofa DF, Hubbard GB, Hummelen M, Husakova K, Hussein Al-Janabi AN, Ibanga A, Ida R, Ilic VR, Islamov Z, Jairaj V, Janjua T, Jeeva I, Ji X, Jo DH, Jones MM, Kabesha Amani TB, Kabore RL, Kaliki S, Kalinaki A, Kamsang P, Kantar M, Kapelushnik N, Kardava T, Kebudi R, Keomisy J, Kepak T, Ketteler P, Khan ZJ, Khaqan HA, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivela TT, Klett A, Koç I, Kosh Komba Palet JE, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lam GC, Larson SA, Latinović S, Laurenti KD, Lavy Y, Lavric Groznik A, Leverant AA, Li C, Li K, Limbu B, Liu CH, Quah B, López JP, Lukamba RM, Luna-Fineman S, Lutfi D, Lysytsia L, Madgar S, Magrath GN, Mahajan A, Maitra P, Maka E, Makimbetov EK, Maktabi A, Maldonado C, Mallipatna A, Manudhane R, Manzhuova L, Martín-Begue N, Masud S, Matende IO, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Mehrvar A, Mengesha AA, Menon V, Mercado GJV, Mets MB, Midena E, Miller A, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KIM, Munier FL, Murray TG, Musa KO, Mushtaq A, Musika AA, Mustak H, Mustapha T, Muyen OM, Myezo KH, Naidu G, Naidu N, Nair AG, Natarajan S, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ng Y, Nikitovic M, Nkanga ED, Nkumbe HE, Numbi MN, Nummi K, Nuruddin M, Nyaywa M, Nyirenda C, Obono-Obiang G, Oliver SCN, Oporto J, Ortega-Hernández M, Oscar AH, Ossandon D, Pagarra H, Paintsil V, Paiva L, Palanivelu MS, Papyan R, Parrozzani R, Pascual Morales CR, Paton KE, Pe'er J, Peralta Calvo J, Perić S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov V, Ponce J, Qadir AO, Qayyum S, Qian J, Refaeli D, Rahman A, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Randhawa JK, Randrianarisoa HL, Raobela L, Rashid R, Reddy M, Renner LA, Reynders D, Ribadu D, Ritter-Sovinz P, Rogowska A, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sanchez Orozco AJ, Sayalith P, Scanlan TA, Schlüter S, Schwab C, Sedaghat A, Seth R, Sgroi M, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shields CL, Sia D, Siddiqui SN, Sidi cheikh S, Silva S, Singh AD, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Steinberg DM, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tang J, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Teh KH, Tehuteru ES, Teixeira LF, Tekavcic Pompe M, Thawaba ADM, Theophile T, Toledano H, Trang DL, Traoré F, Tripathy D, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, Valente P, van Hoefen Wijsard M, Vasquez Anchaya JK, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Villegas VM, Vishnevskia-Dai V, Waddell K, Wali AH, Wang YZ, Wangtiraumnuay N, Wetter J, Widiarti W, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wong ES, Wongwai P, Wu SQ, Xiang D, Xiao Y, Xu B, Xue K, Yaghy A, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yee RI, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang Y, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet Global Health 2022; 10:e1128-e1140. [PMID: 35839812 PMCID: PMC9397647 DOI: 10.1016/s2214-109x(22)00250-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 05/06/2022] [Accepted: 05/23/2022] [Indexed: 02/01/2023] Open
Abstract
Background Retinoblastoma is the most common intraocular cancer worldwide. There is some evidence to suggest that major differences exist in treatment outcomes for children with retinoblastoma from different regions, but these differences have not been assessed on a global scale. We aimed to report 3-year outcomes for children with retinoblastoma globally and to investigate factors associated with survival. Methods We did a prospective cluster-based analysis of treatment-naive patients with retinoblastoma who were diagnosed between Jan 1, 2017, and Dec 31, 2017, then treated and followed up for 3 years. Patients were recruited from 260 specialised treatment centres worldwide. Data were obtained from participating centres on primary and additional treatments, duration of follow-up, metastasis, eye globe salvage, and survival outcome. We analysed time to death and time to enucleation with Cox regression models. Findings The cohort included 4064 children from 149 countries. The median age at diagnosis was 23·2 months (IQR 11·0–36·5). Extraocular tumour spread (cT4 of the cTNMH classification) at diagnosis was reported in five (0·8%) of 636 children from high-income countries, 55 (5·4%) of 1027 children from upper-middle-income countries, 342 (19·7%) of 1738 children from lower-middle-income countries, and 196 (42·9%) of 457 children from low-income countries. Enucleation surgery was available for all children and intravenous chemotherapy was available for 4014 (98·8%) of 4064 children. The 3-year survival rate was 99·5% (95% CI 98·8–100·0) for children from high-income countries, 91·2% (89·5–93·0) for children from upper-middle-income countries, 80·3% (78·3–82·3) for children from lower-middle-income countries, and 57·3% (52·1-63·0) for children from low-income countries. On analysis, independent factors for worse survival were residence in low-income countries compared to high-income countries (hazard ratio 16·67; 95% CI 4·76–50·00), cT4 advanced tumour compared to cT1 (8·98; 4·44–18·18), and older age at diagnosis in children up to 3 years (1·38 per year; 1·23–1·56). For children aged 3–7 years, the mortality risk decreased slightly (p=0·0104 for the change in slope). Interpretation This study, estimated to include approximately half of all new retinoblastoma cases worldwide in 2017, shows profound inequity in survival of children depending on the national income level of their country of residence. In high-income countries, death from retinoblastoma is rare, whereas in low-income countries estimated 3-year survival is just over 50%. Although essential treatments are available in nearly all countries, early diagnosis and treatment in low-income countries are key to improving survival outcomes. Funding Queen Elizabeth Diamond Jubilee Trust.
Collapse
|
4
|
Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 2021; 24:997-1007. [PMID: 34850167 PMCID: PMC9159442 DOI: 10.1093/neuonc/noab274] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. Methods Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). Results As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3–79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16–49) for all patients. The 24-week disease control rate was 73% (95% CI: 54–87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45–100), 56% (95% CI: 38–74), and 85% (95% CI: 71–99), respectively. Median time to response was 1.9 months (range 1.0–3.8 months). Duration of treatment ranged from 1.2–31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3–4 in 3 patients. No new safety signals were identified. Conclusions In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.
Collapse
Affiliation(s)
- François Doz
- SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie and Université de Paris, Paris, France
| | - Cornelis M van Tilburg
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Birgit Geoerger
- Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015, Villejuif, France
| | | | - Ingrid Øra
- Department of Pediatric Oncology, Skåne University Hospital, Lund & Karolinska University Hospital, Stockholm, Sweden
| | - Valentina Boni
- START Madrid CIOCC, HM Hospital Universitario Sanchinarro, Madrid, Spain
| | | | - Julia Chisholm
- Children and Young Peoples Unit, Royal Marsden Hospital, Surrey, United Kingdom
| | - Hyun Cheol Chung
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
| | - Steven G DuBois
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
| | | | - Nicolas U Gerber
- Department of Oncology, University Children's Hospital, Zurich, Switzerland
| | - Hiroaki Goto
- Kanagawa Children's Medical Center, Yokohama, Japan
| | - Juneko E Grilley-Olson
- Lineberger Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA
| | - Jordan R Hansford
- Royal Children's Hospital Melbourne, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia
| | - David S Hong
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | | | - Hyoung Jin Kang
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - Karsten Nysom
- Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Anne Thorwarth
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Joanna Stefanowicz
- Department of Paediatrics, Hematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
| | - Makoto Tahara
- National Cancer Center Hospital East, Kashiwa, Japan
| | - David S Ziegler
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia.,School of Women's and Children's Health, University of New South Wales Sydney, Sydney, Australia
| | | | | | - Laura Dima
- Bayer Consumer Care AG, Basel, Switzerland
| | | | - Theodore W Laetsch
- Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center/Children's Health, Dallas, Texas, USA.,Current affiliation: The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Alexander Drilon
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Weill Cornell Medical College, New York, New York, USA
| | | |
Collapse
|
5
|
Doz F, van Tilburg CM, Geoerger B, Nysom K, Øra I, Boni V, Chisholm J, Chung HC, DuBois SG, Melcón SG, Gerber NU, Goto H, Grilley-Olsen JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Capra M, Schulte JH, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S. CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.283] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a first-in-class, highly selective TRK inhibitor approved for patients with TRK fusion cancer, with a 75% objective response rate (ORR) in 206 evaluable patients with various non-CNS cancers (Hong et al, ASCO 2021). We report data on patients with TRK fusion-positive primary CNS tumors.
METHODS
Patients with TRK fusion-positive primary CNS tumors in 2 clinical trials (NCT02637687, NCT02576431) were identified. Objective responses were investigator-assessed.
RESULTS
As of July 2020, 33 patients with TRK fusion-positive primary CNS tumors were identified (19 high-grade gliomas [HGG], 8 low-grade gliomas [LGG], 2 glioneuronal tumors, 2 neuroepithelial tumors, 1 CNS neuroblastoma, 1 small round blue cell tumor). Median age was 8.9 years (range 1.3-79.0). Patients were heavily pre-treated, with 45% having ≥ 2 prior systemic therapies. ORR was 30% (95% CI 16-49): 3 complete responses (all pediatric), 7 partial responses, 20 stable disease, and 3 progressive disease. ORR in patients with HGG and LGG were 26% (95% CI 9-51) and 38% (95% CI 9-76), respectively. Median time to response was 1.9 months. Responses were seen regardless of the number of prior systemic therapies. The 24-week disease control rate was 73% (95% CI 54-87). Median PFS was 18.3 months (95% CI 6.7-not estimable [NE]) and median overall survival (OS) was not reached (95% CI 16.9-NE) at a median follow-up of 16.5 months; 12-month OS rate was 85% (95% CI 71-99). Treatment duration ranged from 1.2 to 31.3+ months. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 3 patients (9%). There were no treatment discontinuations due to TRAEs.
CONCLUSIONS
In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and favorable safety regardless of age or number of prior systemic therapies.
Collapse
Affiliation(s)
- François Doz
- Institut Curie and University of Paris, Paris, France
| | - Cornelis M van Tilburg
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Birgit Geoerger
- Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France
| | - Karsten Nysom
- Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Ingrid Øra
- Department of Pediatric Oncology, Skåne University Hospital, Lund & Karolinska University Hospital, Stockholm, Sweden
| | - Valentina Boni
- START Madrid CIOCC, HM Hospital Universitario Sanchinarro, Madrid, Spain
| | - Julia Chisholm
- Children and Young Peoples Unit, Royal Marsden Hospital, Madrid, Spain
| | - Hyun Cheol Chung
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Steven G DuBois
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA
| | | | | | - Hiroaki Goto
- Kanagawa Children’s Medical Center, Yokohama, Japan
| | | | - Jordan R Hansford
- Royal Children’s Hospital Melbourne, Murdoch Children’s Research Institute, University of Melbourne, Melbourne, VIC, Australia
| | - David S Hong
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Antoine Italiano
- Early Phase Trials Unit, Institut Bergonie, Bordeaux, France; University of Bordeaux, Bordeaux, France
| | - Hyoung Jin Kang
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | | | - Johannes H Schulte
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Joanna Stefanowicz
- Department of Paediatrics, Hematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
| | - Makoto Tahara
- National Cancer Center Hospital East, Kashiwa, Japan
| | - David S Ziegler
- Sydney Children’s Hospital, Randwick, NSW, Australia
- School of Women’s and Children’s Health, University of New South Wales, Sydney, NSW, Australia
| | | | | | - Laura Dima
- Bayer Consumer Care AG, Basel, Switzerland
| | | | - Theodore W Laetsch
- The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
| | - Alexander Drilon
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | | |
Collapse
|
6
|
Besani C, Dunne A, D'Arcy-Bewick S, Owens C, Pears J, O'Marcaigh A, Malone A, Fortune G, Capra M, Smith OP. The Development of a National Paediatric Psycho-Oncology Service. Ir Med J 2021; 114:400. [PMID: 34520155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Aims To investigate the psychological care provided to children and young adolescents with cancer and their families within the National Children's Cancer Service (NCCS), Ireland, in respect of the national and international standards of care. Methods A retrospective audit of 316 referrals made over 32 months by the NCCS to the psychology service in malignant haematology and oncology was performed. Results The audit revealed that out of 316 patients, a yearly average of 189 (50%) of urgently referred patients received psychological support within the NCCS between January 2013 and August 2016. Furthermore only 20 (22%) undergoing haematopoietic stem cell transplantation (HSCT), 14 (22%) referred to the paediatric palliative care team, and 84 (62%) of teenage patients received psychological input during this timeframe. Conclusion The audit revealed that the current psychology service provision is failing to meet the international standards of care. Due to the data provided by this audit, in conjunction with a clinical risk assessment of the service, funds for the post of principal psychologist have been secured. Further psychology posts (HSCT, late-effects and neuropsychology), and development of the psycho-oncology model of care are required to ensure equality of access and evidence-based psychological care for all children with cancer.
Collapse
Affiliation(s)
- C Besani
- National Children's Cancer Service, Children's Health Ireland at Crumlin
- Paediatric Psychology Department, Children's Health Ireland at Crumlin
- National Children's Research Centre
| | - A Dunne
- National Children's Cancer Service, Children's Health Ireland at Crumlin
- Paediatric Psychology Department, Children's Health Ireland at Crumlin
- National Children's Research Centre
| | - S D'Arcy-Bewick
- Paediatric Psychology Department, Children's Health Ireland at Crumlin
| | - C Owens
- National Children's Cancer Service, Children's Health Ireland at Crumlin
| | - J Pears
- National Children's Cancer Service, Children's Health Ireland at Crumlin
| | - A O'Marcaigh
- National Children's Cancer Service, Children's Health Ireland at Crumlin
| | - A Malone
- National Children's Cancer Service, Children's Health Ireland at Crumlin
| | - G Fortune
- Paediatric Psychology Department, Children's Health Ireland at Crumlin
| | - M Capra
- National Children's Cancer Service, Children's Health Ireland at Crumlin
| | - O P Smith
- National Children's Cancer Service, Children's Health Ireland at Crumlin
- National Children's Research Centre
| |
Collapse
|
7
|
Zinzani PL, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang M, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Mongay Soler L, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Matasar MJ. CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB
VS
RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL). Hematol Oncol 2021. [DOI: 10.1002/hon.24_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. L. Zinzani
- IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Università di Bologna, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Bologna Italy
| | - M. Capra
- Hospital Mãe de Deus Centro de Hematologia e Oncologia Porto Alegre Brazil
| | - M. Özcan
- Ankara University School of Medicine Hematology Department Ankara Turkey
| | - F. Lv
- Fudan University Shanghai Cancer Center Department of Medical Oncology Shanghai China
| | - W. Li
- The First Hospital of Jilin University Department of Hematology Changchun China
| | - E. Yañez
- University of La Frontera, Department of Internal Medicine Oncology‐Hematology Unit Temuco Chile
| | - K. Sapunarova
- Medical University Department of Internal Medicine Hematology Division Plovdiv Bulgaria
| | - T. Lin
- Sun Yat‐sen University Cancer Center Department of Medical Oncology Guangzhou China
| | - J. Jin
- The First Affiliated Hospital of Zhejiang University College of Medicine Department of Hematology Hangzhou China
| | - W. Jurczak
- Maria Skłodowska‐Curie National Research Institute of Oncology Department of Clinical Oncology Krakow Poland
| | - A. Hamed
- Petz Aladár Megyei Oktató Kórház Hematológiai Osztály Gyor Hungary
| | - M.‐C. Wang
- Chang Gung Memorial Hospital Kaohsiung Department of Medicine Kaohsiung Taiwan
| | - R. Baker
- Perth Blood Institute, Murdoch University Western Australia Centre for Thrombosis and Haemostasis Perth Australia
| | - I. Bondarenko
- City Dnipropetrovsk Multi‐field Clinical Hospital 4 DSMA, Chemotherapy Department Dnipro Ukraine
| | - Q. Zhang
- Harbin Medical University Cancer Hospital Department of Medical Oncology Harbin China
| | - J. Feng
- Jiangsu Cancer Hospital Department of Medical Oncology Nanjing China
| | - K. Geissler
- Sigmund Freud University, 5th Medical Department with Hematology Oncology and Palliative Medicine Vienna Austria
| | - M. Lazaroiu
- S.C. Policlinica de Diagnostic Rapid S.A. Department of Hematology Brasov Romania
| | - G. Saydam
- Ege Üniversitesi Tıp Fakültesi Division of Hematology Izmir Turkey
| | - Á. Szomor
- Pécsi Tudományegyetem Klinikai Központ 1st Department of Internal Medicine Pécs Hungary
| | - K. Bouabdallah
- University Hospital of Bordeaux Hematology and Cellular Therapy Department Bordeaux France
| | - R. Galiulin
- Clinical Oncological Dispensary of Omsk Region Department of Chemotherapy for Children and Adults Omsk Russian Federation
| | - T. Uchida
- Japanese Red Cross Nagoya Daini Hospital Department of Hematology and Oncology Nagoya Japan
| | - L. Mongay Soler
- Bayer HealthCare Pharmaceuticals, Inc. Clinical Development Whippany USA
| | - A. Cao
- Bayer HealthCare Pharmaceuticals, Inc. Clinical Statistics Whippany USA
| | - F. Hiemeyer
- Pharmaceuticals Division, Bayer AG Clinical Statistics Berlin Germany
| | - A. Mehra
- Bayer HealthCare Pharmaceuticals, Inc. Clinical Development Whippany USA
| | - B. H. Childs
- Bayer HealthCare Pharmaceuticals, Inc. Clinical Development Whippany USA
| | - Y. Shi
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Department of Medical Oncology Beijing China
| | - M. J. Matasar
- Memorial Sloan Kettering Cancer Center Department of Medicine New York USA
| |
Collapse
|
8
|
Perreault S, Doz F, Geoerger B, Nysom K, Øra I, Boni V, Chisholm J, DuBois SG, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Kang HJ, Capra M, Schulte JH, Stefanowicz J, Tahara M, Ziegler DS, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, van Tilburg CM. RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro Oncol 2021. [PMCID: PMC8168097 DOI: 10.1093/neuonc/noab090.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with TRK fusion cancer, with an objective response rate (ORR) of 78% across multiple non-CNS cancers (McDermott et al, ESMO 2020). We report updated data on pediatric patients with TRK fusion-positive primary CNS tumors. Methods Patients aged <18 years with primary CNS tumors harboring an NTRK gene fusion enrolled in two clinical trials (NCT02637687, NCT02576431) were identified. Larotrectinib was administered until disease progression, withdrawal, or unacceptable toxicity. Response was investigator assessed. Results By July 2020, 26 pediatric patients with TRK fusion-positive CNS tumors were treated. Tumor histologic subtypes included high-grade glioma (n=13), low-grade glioma (n=7), glioneuronal tumor (n=2), neuroepithelial tumor (n=2), CNS neuroblastoma (n=1), and small round blue cell tumor (n=1). Median age was 7.0 years (range 1.3–16.7). The ORR was 38% (95% CI 20–59%): 3 complete responses, 7 partial responses (including 2 pending confirmation), 14 stable disease, and 2 progressive disease. The ORR in patients with high-grade glioma was 38% (95% CI 14–68%). Nineteen of 21 patients (90%) with measurable disease had tumor shrinkage. The 24-week disease control rate was 77% (95% CI 56–91%). Median duration of response (DoR), PFS and overall survival (OS) were not reached. The 12-month rates for DoR, PFS and OS were 75%, 65%, and 86%, respectively. Duration of treatment ranged from 1.2 to 31.3+ months. Treatment-related adverse events were reported for 15 patients (58%) and were Grade 3–4 in 3 patients (12%), with no discontinuations related to larotrectinib. Conclusions In pediatric patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated durable responses, high disease control rate, and good tolerability. These results support testing for NTRK gene fusions in pediatric patients with CNS tumors.
Collapse
Affiliation(s)
| | - François Doz
- Institut Curie and University of Paris, Paris, France
| | - Birgit Geoerger
- Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France
| | - Karsten Nysom
- Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Ingrid Øra
- Department of Pediatric Oncology, Skåne University Hospital, Lund & Karolinska University Hospital, Lund, Sweden
| | - Valentina Boni
- START Madrid CIOCC, HM Hospital Universitario Sanchinarro, Madrid, Spain
| | - Julia Chisholm
- Children and Young Peoples Unit, Royal Marsden Hospital, Surrey, UK
| | - Steven G DuBois
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
| | - Nicolas U Gerber
- Department of Oncology, University Children’s Hospital, Zurich, Switzerland
| | - Hiroaki Goto
- Kanagawa Children’s Medical Center, Yokohama, Japan
| | | | - Jordan R Hansford
- Royal Children’s Hospital Melbourne, Murdoch Children’s Research Institute, University of Melbourne, Melbourne, VA, Australia
| | - Hyoung Jin Kang
- Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul, Korea, Republic of
| | - Michael Capra
- Department of Haemato-Oncology, Our Lady’s Children’s Hospital, Dublin, Ireland
| | - Johannes H Schulte
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Joanna Stefanowicz
- Department of Paediatrics, Hematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
| | - Makoto Tahara
- National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | - Laura Dima
- Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland
| | | | - Theodore W Laetsch
- The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA, USA
| | - Cornelis M van Tilburg
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
9
|
Javadpour M, Amoo M, Crimmins D, Caird J, Daly P, Pears J, Owens C, Capra M, Cody D. Endoscopic extended transsphenoidal surgery for newly diagnosed paediatric craniopharyngiomas. Childs Nerv Syst 2021; 37:1547-1561. [PMID: 33665678 DOI: 10.1007/s00381-021-05108-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 03/01/2021] [Indexed: 12/25/2022]
Abstract
PURPOSE Endoscopic extended transsphenoidal surgery (EETSS) has gained popularity for treatment of craniopharyngiomas. The aim of this study is to assess the outcome of endoscopic extended transsphenoidal surgery (EETSS) for newly diagnosed paediatric craniopharyngiomas. METHODS Patient details were obtained from a prospective database of all endoscopic transnasal operations performed by a single surgeon. Outcomes including visual function, pituitary function, body mass index (BMI), postoperative neurological deficit, extent of resection and recurrence on follow-up were obtained. Obesity was defined as BMI percentile of equal to or greater than 95%. RESULTS Between January 2011 and January 2020, 15 of 16 children (5-18 years old) with newly diagnosed craniopharyngiomas underwent EETSS. Four patients had a conchal-type sphenoid sinus. Gross total resection (GTR) was achieved in 4 patients and near total resection (NTR) in 5 patients. The remaining 6 had subtotal resection (STR). Postoperative radiotherapy was used in 6 patients (4 with STR, 2 with NTR). There were no postoperative deaths, strokes or CSF leaks. Normalisation of visual fields (VF) occurred in 9/13 patients with preoperative VF defects. One patient developed a new visual field defect. During a median follow-up period of 74 (8-104) months, 2 patients have required further surgery for tumour progression following initial STR, where a tumour remnant was left in situ to preserve the pituitary stalk. 6/11 patients developed new anterior pituitary dysfunction as a result of surgery and 9/12 developed new diabetes insipidus (DI). At the time of last follow-up, 14/15 children had anterior panhypopituitarism, 13/15 had DI and 1 patient developed new onset obesity. Two patients, who were obese preoperatively, were no longer obese at last follow-up. CONCLUSIONS EETSS can be performed as the first option in the majority of children with newly diagnosed craniopharyngioma, despite factors such as small nose, non-pneumatised sphenoid sinus, small sella or purely suprasellar tumour location. Preservation of the pituitary stalk at the expense of leaving residual tumour may not be in the best interests of the patient.
Collapse
Affiliation(s)
- Mohsen Javadpour
- National Neurosurgical Centre, Beaumont Hospital, Dublin, Ireland.
- Trinity College Dublin, Dublin, Ireland.
- Royal College of Surgeons in Ireland, Dublin, Ireland.
| | - Michael Amoo
- National Neurosurgical Centre, Beaumont Hospital, Dublin, Ireland
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Darach Crimmins
- National Neurosurgical Centre, Beaumont Hospital, Dublin, Ireland
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - John Caird
- National Neurosurgical Centre, Beaumont Hospital, Dublin, Ireland
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Patricia Daly
- Trinity College Dublin, Dublin, Ireland
- St Luke's Radiation Oncology Network, Dublin, Ireland
| | - Jane Pears
- Departments of Paediatric Oncology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Cormac Owens
- Departments of Paediatric Oncology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Michael Capra
- Departments of Paediatric Oncology, Children's Health Ireland at Crumlin, Dublin, Ireland
| | - Declan Cody
- Departments of Paediatric Endocrinology, Children's Health Ireland at Crumlin, Dublin, Ireland
| |
Collapse
|
10
|
Capra M, Lodesani A, Brambilla A, Finazzi M, Duò L, Ciccacci F, Picone A. Reversible metamorphosis from Fe 3O 4 to FeO of epitaxial iron oxide films grown on the Fe-p(1 × 1)O surface. RSC Adv 2021; 11:11513-11518. [PMID: 35423610 PMCID: PMC8698807 DOI: 10.1039/d0ra10650j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 03/12/2021] [Indexed: 01/08/2023] Open
Abstract
The reduction and oxidation of epitaxial Fe3O4 films grown by reactive deposition on a Fe-p(1 × 1)O surface have been investigated by means of Auger electron spectroscopy (AES), low energy electron diffraction (LEED) and scanning tunneling microcopy (STM). The as-grown iron oxide samples display a square LEED pattern with a lattice constant compatible with a p(1 × 1) bulk terminated Fe3O4(001) surface. STM topographic images of Fe3O4 are characterized by atomically flat terraces separated by highly oriented steps running along the (010) and (100) crystallographic directions of the substrate. Upon annealing at 800 K in an ultra-high vacuum, AES reveals that magnetite transforms to FeO. The sample exposes the (001) surface of the rock salt structure, with a lattice parameter close to that of bulk wüstite. The Fe3O4 phase can be recovered by oxidation at 10−6 mbar of molecular oxygen. The reduction and oxidation of epitaxial Fe3O4 films grown by reactive deposition on a Fe-p(1 × 1)O surface have been investigated by means of surface science techniques.![]()
Collapse
Affiliation(s)
- M. Capra
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - A. Lodesani
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - A. Brambilla
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - M. Finazzi
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - L. Duò
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - F. Ciccacci
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| | - A. Picone
- Department of Physics
- Politecnico di Milano
- I-20133 Milano
- Italy
| |
Collapse
|
11
|
Chew S, Gleeson JP, McCarthy A, Watson GA, O'Dwyer R, Nicholson S, Capra M, Owens C, McDermott M, Daly P, Grant C. Leptomeningeal Relapse of Embryonal Rhabdomyosarcoma after 15 years. Ir Med J 2020; 112:1026. [PMID: 32311247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Aim Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumour of childhood. We present the case of a late relapse of RMS to the leptomeninges after 15 years. Methods A 20 year old male presented with a 3 week history of headaches and nausea. He previously had RMS of his right ear diagnosed at age 5 years which was treated with concurrent chemoradiotherapy. An MRI Brain and Spine confirmed extensive leptomeningeal disease and CSF analysis confirmed the presence of recurrent embryonal RMS. Results He completed two cycles of cyclophosphamide and topotecan followed by 45Gy/25Fr of craniospinal radiotherapy. Conclusion Late relapses beyond five years can be seen in up to 9% of patients, however very late recurrences (>10 years) are exceedingly rare. Molecular based methods such as gene expression profiling can aid risk stratification and survivorship clinics may become increasingly useful in following patients with high risk features.
Collapse
Affiliation(s)
- S Chew
- Department of Medical Oncology, St James's Hospital, Dublin 8, Ireland
| | - J P Gleeson
- Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland
| | - A McCarthy
- Department of Medical Oncology, St James's Hospital, Dublin 8, Ireland
| | - G A Watson
- Department of Medical Oncology, St James's Hospital, Dublin 8, Ireland
| | - R O'Dwyer
- Department of Medical Oncology, St James's Hospital, Dublin 8, Ireland
| | - S Nicholson
- Department of Histopathology, St James's Hospital, Dublin 8, Ireland
| | - M Capra
- Department of Medical Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | - C Owens
- Department of Medical Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | - M McDermott
- Department of Histopathology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | - P Daly
- Department of Radiation Oncology, St James's Hospital, Dublin 8, Ireland
| | - C Grant
- Department of Medical Oncology, St James's Hospital, Dublin 8, Ireland
| |
Collapse
|
12
|
Goto H, Geoerger B, DuBois SG, Grilley-Olson JE, van Tilburg CM, Schulte J, Kang HJ, Tahara M, Boni V, Perreault S, Capra M, Reeves JA, Brega N, Childs BH, Laetsch TW, Ziegler DS, Doz F. EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro Oncol 2020. [PMCID: PMC7715507 DOI: 10.1093/neuonc/noaa222.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND TRK fusions are oncogenic drivers in a variety of tumors, many involving the CNS. Larotrectinib, a selective FDA- and EMA-approved TRK inhibitor, demonstrated a 79% objective response rate (ORR) and a 35.2-month median duration of response (DoR) in adult and pediatric patients with various non-CNS solid tumors harboring NTRK gene fusions. We report the clinical activity of larotrectinib in pediatric patients with primary TRK fusion CNS tumors. METHODS Patients aged <18 years with primary CNS tumors harboring an NTRK gene fusion detected by local molecular testing who were treated with larotrectinib in two clinical trials (NCT02637687, NCT02576431) were identified. Larotrectinib was administered until disease progression, withdrawal, or unacceptable toxicity. Disease status was investigator assessed (RANO). RESULTS As of February 2019, 14 pediatric patients with primary TRK fusion CNS tumors were identified. Gene fusions involved NTRK2 (n=10), NTRK1 (n=2), and NTRK3 (n=2). Median age was 7.0 years (range 1.3–16.7). ORR was 45% (95% CI 17–77%) among 11 evaluable patients. Two patients had complete responses (pending confirmation), three had confirmed partial responses, and six had stable disease. 24-week disease control rate was 73%. DoR ranged from 2.6+ to 5.5+ months and progression-free survival ranged from 0.03+ to 13.9+ months. Duration of treatment ranged from 0.03+ to 16.6+ months. Treatment-emergent adverse events were mainly grade 1–2. CONCLUSIONS Larotrectinib resulted in objective responses and durable disease control in pediatric patients with primary TRK fusion CNS tumors. These results support expanded testing for NTRK gene fusions in patients with CNS tumors.
Collapse
Affiliation(s)
- Hiroaki Goto
- Kanagawa Children’s Medical Center, Yokohama, Japan
| | - Birgit Geoerger
- Gustave Roussy, Department of Pediatric and Adolescent Oncology, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Steven G DuBois
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
| | | | - Cornelis M van Tilburg
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Hyoung Jin Kang
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Makoto Tahara
- National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | | | | | | | | | | | | | - François Doz
- Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
| |
Collapse
|
13
|
Clarke M, Mackay A, Ismer B, Pickles JC, Tatevossian RG, Newman S, Bale TA, Stoler I, Izquierdo E, Temelso S, Carvalho DM, Molinari V, Burford A, Howell L, Virasami A, Fairchild AR, Avery A, Chalker J, Kristiansen M, Haupfear K, Dalton JD, Orisme W, Wen J, Hubank M, Kurian KM, Rowe C, Maybury M, Crosier S, Knipstein J, Schüller U, Kordes U, Kram DE, Snuderl M, Bridges L, Martin AJ, Doey LJ, Al-Sarraj S, Chandler C, Zebian B, Cairns C, Natrajan R, Boult JKR, Robinson SP, Sill M, Dunkel IJ, Gilheeney SW, Rosenblum MK, Hughes D, Proszek PZ, Macdonald TJ, Preusser M, Haberler C, Slavc I, Packer R, Ng HK, Caspi S, Popović M, Faganel Kotnik B, Wood MD, Baird L, Davare MA, Solomon DA, Olsen TK, Brandal P, Farrell M, Cryan JB, Capra M, Karremann M, Schittenhelm J, Schuhmann MU, Ebinger M, Dinjens WNM, Kerl K, Hettmer S, Pietsch T, Andreiuolo F, Driever PH, Korshunov A, Hiddingh L, Worst BC, Sturm D, Zuckermann M, Witt O, Bloom T, Mitchell C, Miele E, Colafati GS, Diomedi-Camassei F, Bailey S, Moore AS, Hassall TEG, Lowis SP, Tsoli M, Cowley MJ, Ziegler DS, Karajannis MA, Aquilina K, Hargrave DR, Carceller F, Marshall LV, von Deimling A, Kramm CM, Pfister SM, Sahm F, Baker SJ, Mastronuzzi A, Carai A, Vinci M, Capper D, Popov S, Ellison DW, Jacques TS, Jones DTW, Jones C. Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discov 2020; 10:942-963. [PMID: 32238360 PMCID: PMC8313225 DOI: 10.1158/2159-8290.cd-19-1030] [Citation(s) in RCA: 138] [Impact Index Per Article: 34.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 03/03/2020] [Accepted: 03/20/2020] [Indexed: 11/16/2022]
Abstract
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, genome, or exome sequencing. After excluding tumors representing other established entities or subgroups, we identified 130 cases to be part of an "intrinsic" spectrum of disease specific to the infant population. These included those with targetable MAPK alterations, and a large proportion of remaining cases harboring gene fusions targeting ALK (n = 31), NTRK1/2/3 (n = 21), ROS1 (n = 9), and MET (n = 4) as their driving alterations, with evidence of efficacy of targeted agents in the clinic. These data strongly support the concept that infant gliomas require a change in diagnostic practice and management. SIGNIFICANCE: Infant high-grade gliomas in the cerebral hemispheres comprise novel subgroups, with a prevalence of ALK, NTRK1/2/3, ROS1, or MET gene fusions. Kinase fusion-positive tumors have better outcome and respond to targeted therapy clinically. Other subgroups have poor outcome, with fusion-negative cases possibly representing an epigenetically driven pluripotent stem cell phenotype.See related commentary by Szulzewsky and Cimino, p. 904.This article is highlighted in the In This Issue feature, p. 890.
Collapse
Affiliation(s)
- Matthew Clarke
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Alan Mackay
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Britta Ismer
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
| | - Jessica C Pickles
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Ruth G Tatevossian
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Scott Newman
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Tejus A Bale
- Department of Neuropathology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Iris Stoler
- Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
| | - Elisa Izquierdo
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Sara Temelso
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Diana M Carvalho
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Valeria Molinari
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Anna Burford
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Louise Howell
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Alex Virasami
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Amy R Fairchild
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Aimee Avery
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Jane Chalker
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Mark Kristiansen
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Kelly Haupfear
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - James D Dalton
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Wilda Orisme
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Ji Wen
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Michael Hubank
- Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom
| | - Kathreena M Kurian
- Brain Tumour Research Centre, University of Bristol, Bristol, United Kingdom
| | - Catherine Rowe
- Brain Tumour Research Centre, University of Bristol, Bristol, United Kingdom
| | - Mellissa Maybury
- The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
- Oncology Service, Queensland Children's Hospital, Brisbane, Australia
- Child Health Research Centre, The University of Queensland, South Brisbane, Australia
| | - Stephen Crosier
- Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom
| | - Jeffrey Knipstein
- Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Ulrich Schüller
- Department of Neuropathology, University Hospital Hamburg-Eppendorf, and Research Institute Children's Cancer Center, Hamburg, Germany
- Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Uwe Kordes
- Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - David E Kram
- Section of Pediatric Hematology-Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Matija Snuderl
- Department of Neuropathology, NYU Langone Health, New York, New York
| | - Leslie Bridges
- Department of Neuropathology, St George's Hospital NHS Trust, London, United Kingdom
| | - Andrew J Martin
- Department of Neurosurgery, St George's Hospital NHS Trust, London, United Kingdom
| | - Lawrence J Doey
- Department of Clinical Neuropathology, Kings College Hospital NHS Trust, London, United Kingdom
| | - Safa Al-Sarraj
- Department of Clinical Neuropathology, Kings College Hospital NHS Trust, London, United Kingdom
| | - Christopher Chandler
- Department of Neurosurgery, Kings College Hospital NHS Trust, London, United Kingdom
| | - Bassel Zebian
- Department of Neurosurgery, Kings College Hospital NHS Trust, London, United Kingdom
| | - Claire Cairns
- Department of Neurosurgery, Kings College Hospital NHS Trust, London, United Kingdom
| | - Rachael Natrajan
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Jessica K R Boult
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
| | - Simon P Robinson
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
| | - Martin Sill
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ira J Dunkel
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Stephen W Gilheeney
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Marc K Rosenblum
- Department of Neuropathology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Debbie Hughes
- Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom
| | - Paula Z Proszek
- Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom
| | - Tobey J Macdonald
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
| | - Matthias Preusser
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Christine Haberler
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - Irene Slavc
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Roger Packer
- Center for Neuroscience and Behavioural Medicine, Children's National Medical Center, Washington, DC
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, China
| | - Shani Caspi
- Cancer Research Center, Sheba Medical Center, Tel Aviv, Israel
| | - Mara Popović
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Barbara Faganel Kotnik
- Department of Hematology and Oncology, University Children's Hospital, Ljubljana, Slovenia
| | - Matthew D Wood
- Department of Pathology, Oregon Health & Science University, Portland, Oregon
| | - Lissa Baird
- Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon
| | - Monika Ashok Davare
- Department of Pediatrics, Oregon Health & Science University, Portland, Oregon
| | - David A Solomon
- Department of Pathology, University of California, San Francisco, California
- Clinical Cancer Genomics Laboratory, University of California, San Francisco, California
| | - Thale Kristin Olsen
- Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden
| | - Petter Brandal
- Department of Oncology, Oslo University Hospital, Oslo, Norway
| | - Michael Farrell
- Department of Histopathology, Beaumont Hospital, Dublin, Ireland
| | - Jane B Cryan
- Department of Histopathology, Beaumont Hospital, Dublin, Ireland
| | - Michael Capra
- Paediatric Oncology, Our Lady's Children's Hospital, Dublin, Ireland
| | - Michael Karremann
- Department of Pediatrics, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Jens Schittenhelm
- Institute of Pathology and Neuropathology, University Hospital Tübingen, Germany
| | | | - Martin Ebinger
- Department of Pediatric Hematology and Oncology, University Hospital Tübingen, Germany
| | - Winand N M Dinjens
- Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Kornelius Kerl
- Department of Pediatric Hematology and Oncology, University Hospital Muenster, Germany
| | - Simone Hettmer
- Department of Pediatric Hematology and Oncology, University Hospital Freiburg, Germany
| | - Torsten Pietsch
- Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn, Germany
| | - Felipe Andreiuolo
- Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn, Germany
| | - Pablo Hernáiz Driever
- Department of Paediatric Haematology/Oncology Charité Universitätsmedizin, Berlin, Germany
| | - Andrey Korshunov
- Department of Neuropathology, University Hospital Heidelberg, Germany
| | - Lotte Hiddingh
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Barbara C Worst
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany
| | - Dominik Sturm
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany
| | - Marc Zuckermann
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
| | - Olaf Witt
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany
| | - Tabitha Bloom
- BRAIN UK, University of Southampton, Southampton, United Kingdom
| | - Clare Mitchell
- BRAIN UK, University of Southampton, Southampton, United Kingdom
| | - Evelina Miele
- Department of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Giovanna Stefania Colafati
- Oncological Neuroradiology Unit, Department of Diagnostic Imaging, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | | | - Simon Bailey
- Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom
| | - Andrew S Moore
- The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
- Oncology Service, Queensland Children's Hospital, Brisbane, Australia
- Child Health Research Centre, The University of Queensland, South Brisbane, Australia
| | - Timothy E G Hassall
- Oncology Service, Queensland Children's Hospital, Brisbane, Australia
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia
| | - Stephen P Lowis
- Brain Tumour Research Centre, University of Bristol, Bristol, United Kingdom
| | - Maria Tsoli
- Children's Cancer Institute, University of New South Wales, Sydney, Australia
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia
| | - Mark J Cowley
- Children's Cancer Institute, University of New South Wales, Sydney, Australia
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia
| | - David S Ziegler
- Children's Cancer Institute, University of New South Wales, Sydney, Australia
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia
| | - Matthias A Karajannis
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Kristian Aquilina
- Department of Neurosurgery, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
| | - Darren R Hargrave
- Department of Paediatric Oncology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
| | - Fernando Carceller
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
- Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom
| | - Lynley V Marshall
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
- Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom
| | - Andreas von Deimling
- Department of Neuropathology, University Hospital Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Christof M Kramm
- Division of Pediatric Hematology and Oncology, University Medical Centre Göttingen, Germany
| | - Stefan M Pfister
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany
| | - Felix Sahm
- Department of Paediatric Haematology/Oncology Charité Universitätsmedizin, Berlin, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Suzanne J Baker
- Department of Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Angela Mastronuzzi
- Neuro-oncology Unit, Department of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Andrea Carai
- Oncological Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Maria Vinci
- Department of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - David Capper
- Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Sergey Popov
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
- Department of Pathology, University of Wales Hospital NHS Trust, Cardiff, United Kingdom
| | - David W Ellison
- Department of Neuropathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
| | - Thomas S Jacques
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
| | - David T W Jones
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
| | - Chris Jones
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
| |
Collapse
|
14
|
Alken S, Owens C, Gilham C, Grant C, Pears J, Deady S, O'Marcaigh A, Capra M, O'Mahony D, Smith O, Walsh PM. Survival of childhood and adolescent/young adult (AYA) cancer patients in Ireland during 1994-2013: comparisons by age. Ir J Med Sci 2020; 189:1223-1236. [PMID: 32424602 DOI: 10.1007/s11845-020-02236-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 04/16/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND Some studies indicate that survival of adolescents and young adults (AYA) with cancer may be inferior to that of younger children with similar cancers, possibly related (in part) to differences in access to centralized or standardized treatment. AIMS This study aims to evaluate differences in survival for AYA patients when compared with paediatric patients treated in Ireland over a 20-year time period. METHODS This study compares relative survival for patients diagnosed in Ireland at ages 0-15 (paediatric group) and 16-24 (AYA group) during 1994-2013, followed to the end of 2014, for cancers defined by the International Classification of Childhood Cancer (ICCC) (Third Edition) group or subgroup. Five-year relative survival estimates, and excess hazard ratios (EHR) comparing excess mortality associated with a cancer diagnosis among AYA with that in the paediatric group, are presented. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. RESULTS Significantly higher excess mortality was found for AYA with leukaemias, lymphomas, astrocytomas, malignant bone tumours, and Ewing and related bone sarcomas, soft tissue sarcomas and 'other/unspecified' epithelial cancers, rhabdomyosarcomas, and 'other and unspecified' carcinomas. In contrast, lower excess mortality was found in the AYA group for all cancers and intracranial/intraspinal tumours, and for gliomas other than astrocytomas or ependymomas. Comparing 1994-2003 and 2004-2013 cohorts, age-related survival differences narrowed for lymphoid leukaemias, but widened for all cancers combined and intracranial/intraspinal tumours combined. Centralization of services varied depending upon cancer subtype, with leukaemias, CNS tumours and bone sarcomas most centralized. Within these, improvements in survival for leukaemias and CNS tumours have been seen for the AYA population. CONCLUSIONS Reasons for age-related survival differences, and differences in time-trend by age group, are not clear. The significant narrowing of survival differences by age in more recent years for lymphoid leukaemias reflects a more marked recent increase in survival among AYA. More work is required to explain and improve other age-related survival differences.
Collapse
Affiliation(s)
- Scheryll Alken
- St James's Hospital, Dublin, Ireland.
- Children's Health Ireland, Crumlin, Dublin, Ireland.
| | - Cormac Owens
- Children's Health Ireland, Crumlin, Dublin, Ireland
| | - Charles Gilham
- St Luke's Radiation Oncology Network, Rathgar, Dublin, Ireland
| | | | - Jane Pears
- Children's Health Ireland, Crumlin, Dublin, Ireland
| | | | | | | | | | - Owen Smith
- Children's Health Ireland, Crumlin, Dublin, Ireland
| | | |
Collapse
|
15
|
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, Prom V, Purwanto I, Qadir AO, Qayyum S, Qian J, Rahman A, Rahman S, Rahmat J, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Raobela L, Rashid R, Reddy MA, Reich E, Renner LA, Reynders D, Ribadu D, Riheia MM, Ritter-Sovinz P, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sayalith P, Scanlan TA, Schefler AC, Schoeman J, Sedaghat A, Seregard S, Seth R, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shetye NG, Shields CL, Siddiqui SN, Sidi Cheikh S, Silva S, Singh AD, Singh N, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Stathopoulos C, Stirn Kranjc B, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Sundy M, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Tehuteru ES, Teixeira LF, Teh KH, Theophile T, Toledano H, Trang DL, Traoré F, Trichaiyaporn S, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, van Hoefen Wijsard M, Varadisai A, Vasquez L, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Vishnevskia-Dai V, Vora T, Wachtel AE, Wackernagel W, Waddell K, Wade PD, Wali AH, Wang YZ, Weiss A, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wongwai P, Xiang D, Xiao Y, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang C, Zhang Y, Zhao J, Zheng X, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol 2020; 6:685-695. [PMID: 32105305 PMCID: PMC7047856 DOI: 10.1001/jamaoncol.2019.6716] [Citation(s) in RCA: 144] [Impact Index Per Article: 36.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Importance Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.
Collapse
Affiliation(s)
| | - Ido Didi Fabian
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | - Elhassan Abdallah
- Ophthalmology Department of Rabat, Mohammed V University, Rabat, Morocco
| | | | | | | | | | - Adedayo Adio
- Department of Ophthalmology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
| | | | | | - Ada E Aghaji
- Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria
| | - Alia Ahmad
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | | | - Lamis Al Harby
- The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
| | | | - Aygun Alakbarova
- Zarifa Aliyeva National Center of Ophthalmology, Baku, Azerbaijan
| | | | - Safaa A F Al-Badri
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | | | | | - Amanda Alejos
- Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala
| | | | | | | | - Christiane Al-Haddad
- Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon
| | | | - Amany M Ali
- Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
| | - Donjeta B Alia
- University Hospital Center Mother Theresa, Tirana, Albania
| | - Mazin F Al-Jadiry
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | | | - Hind M Alkatan
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | | | | | | | | | | | | | | | | | - Nicholas J Astbury
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Hatice T Atalay
- Department of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
| | | | - Rose Atsiaya
- Lighthouse For Christ Eye Centre, Mombasa, Kenya
| | - Taweevat Attaseth
- Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Than H Aung
- Yangon Eye Hospital, University of Medicine 1, Yangon, Myanmar
| | | | - Baglan Baizakova
- Scientific Center of Pediatrics and Pediatric Surgery, Almaty, Kazakhstan
| | - Julia Balaguer
- Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | - Walentyna Balwierz
- Institute of Pediatrics, Jagiellonian University Medical College, Children's University Hospital of Krakow, Krakow, Poland
| | - Honorio Barranco
- Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Covadonga Bascaran
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Maja Beck Popovic
- Pediatric Hematology-Oncology Unit, Lausanne University Hospital, Lausanne, Switzerland
| | - Raquel Benavides
- Hospital Nacional de Niños Dr Carlos Sáenz Herrera, San Jose, Costa Rica
| | - Sarra Benmiloud
- Department of Pediatric Oncology, University Hassan II Fès, Fez, Morocco
| | | | - Rokia C Berete
- Ophthalmologic Department of the Teaching Hospital of Treichville, Abidjan, Côte d'Ivoire
| | - Jesse L Berry
- Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles
| | | | - Sunil Bhat
- Department of Pediatric Hematology and Oncology, Narayana Health City, Bangalore, India
| | | | - Eva M Biewald
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - Nadia Bobrova
- The Filatov Institute of Eye Diseases and Tissue Therapy, Odessa, Ukraine
| | - Marianna Boehme
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - H C Boldt
- Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City
| | | | - Norbert Bornfeld
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - Gabrielle C Bouda
- Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou, Ouagadougou, Burkina Faso
| | - Hédi Bouguila
- Institut Hédi Raïs d'Ophtalmologie, Faculté de Médecine, Université Tunis El Manar, Tunis, Tunisia
| | - Amaria Boumedane
- Etablissement Hospitalière Spécialise Emir Abdelkader CEA Service d'Oncologie Pédiatrique, Oran, Algeria
| | - Rachel C Brennan
- Solid Tumor Division, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | | | | | | | | | - Jayne E Camuglia
- Department of Ophthalmology, Queensland Children's Hospital, Brisbane, Queensland, Australia
| | - Miriam R Cano
- Salud Ocular, Ministerio de Salud Publica, Asuncion, Paraguay
| | | | - Nathalie Cassoux
- Institut Curie, Université de Paris Medicine Paris V Descartes, Paris, France
| | - Guilherme Castela
- Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
| | | | | | - Guillermo L Chantada
- Hospital Sant Joan de Déu, Barcelona, Spain
- Hospital Garrahan, Buenos Aires, Argentina
- NationalScientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Shabana Chaudhry
- Paediatric Ophthalmology Department, Mayo Hospital and College of Allied Visual Sciences, King Edward Medical University, Lahore, Pakistan
| | - Sonal S Chaugule
- Department of Ophthalmic Plastic Surgery, Orbit and Ocular Oncology, PBMA's H. V. Desai Eye Hospital, Pune, Maharashtra, India
| | | | - Bhavna Chawla
- Ocular Oncology Service, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
| | - Violeta S Chernodrinska
- Eye Clinic, Department of Ophthalmology, University Hospital Alexandrovska, Medical University, Sofia, Sofia, Bulgaria
| | | | | | - Krzysztof Cieslik
- Department of Ophthalmology, The Children's Memorial Health Institute, Warsaw, Poland
| | | | - Codruta Comsa
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | - Zelia M Correa
- Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | | | | | | | | | - Xuehao Cui
- Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | | | - Wantanee Dangboon
- Department of Ophthalmology, Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand
| | - Anirban Das
- Department of Pediatric Hematology-Oncology, Tata Medical Center, Kolkata, India
| | - Sima Das
- Ocular Oncology Services, Dr Shroff's Charity Eye Hospital, New Delhi, India
| | | | - Alan Davidson
- Red Cross War Memorial Children's Hospital and the University of Cape Town, Cape Town, South Africa
| | | | | | - Hakan Demirci
- Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor
| | | | | | - Helen Dimaras
- The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Andrew J Dodgshun
- Department of Paediatrics, University of Otago, Christchurch, Children's Haematology and Oncology Center, Christchurch Hospital, Christchurch, New Zealand
| | - Craig Donaldson
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
| | | | - Monica D Dragomir
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | - Yi Du
- Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | | | - Kemala S Edison
- Ophthalmology Department, Dr M. Djamil General Hospital, Faculty of Medicine, Andalas University, West Sumatra, Indonesia
| | - I Wayan Eka Sutyawan
- Department of Ophthalmology, Faculty of Medicine, Udayana University, Sanglah Eye Hospital, Bali, Indonesia
| | - Asmaa El Kettani
- Center Hospitalier et Universitaire Ibn Rochd, Casablanca, Morocco
| | - Amal M Elbahi
- Tripoli Eye Hospital, University of Tripoli, Tripoli, Libya
| | - James E Elder
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Department of Paediatrics, Melbourne Medical School, University of Melbourne, Parkville, Victoria, Australia
| | - Dina Elgalaly
- Children's Cancer Hospital Egypt 57357, Cairo, Egypt
| | | | - Moawia M Ali Elhassan
- Department of Oncology, National Cancer Institute, University of Gezira, Wadi Madani, Sudan
| | - Mahmoud M Elzembely
- Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
| | - Vera A Essuman
- Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, University of Ghana, Accra, Ghana
| | | | | | | | - Mohammad Faranoush
- Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Rasool Akram Hospital, Tehran, Iran
| | - Oluyemi Fasina
- Department of Ophthalmology, University College Hospital, University of Ibadan, Ibadan, Nigeria
| | | | | | - Allen Foster
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Shahar Frenkel
- Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
| | | | - Soad L Fuentes-Alabi
- Pediatric Oncology Department, Benjamin Bloom National Children's Hospital, San Salvador, El Salvador
| | | | - Moira Gandiwa
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | | | | | | | - Jennifer A Geel
- Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
| | - Fariba Ghassemi
- Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Ana V Girón
- Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala
| | - Zelalem Gizachew
- Department of Ophthalmology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | - Marco A Goenz
- Pediatric Oncology Department, Benjamin Bloom National Children's Hospital, San Salvador, El Salvador
| | - Aaron S Gold
- Murray Ocular Oncology and Retina, Miami, Florida
| | | | - Glen A Gole
- Department of Ophthalmology, Queensland Children's Hospital, Brisbane, Queensland, Australia
| | - Nir Gomel
- Department of Ophthalmology, Sourasky Medical Center Tel Aviv, School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Efren Gonzalez
- Department of Ophthalmology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | - Henry N Garcia Pacheco
- Pediatric Oncology Unit, Instituto Regional de Enfermedades Neoplásicas del Sur, Arequipa, Perú
| | - Jaime Graells
- Unidad de Oncologia Ocular Hospital Oncologico Luis Razzetti, Caracas, Venezuela
| | - Liz Green
- IAM NOOR Eye Care Programme, Afghanistan
| | - Pernille A Gregersen
- Department of Clinical Genetics and Center for Rare Disorders, Aarhus University Hospital, Aarhus, Denmark
| | | | - Koffi M Guedenon
- Département de Pédiatrie, CHU Sylvanus Olympio, Université de Lomé, Lomé, Togo
| | | | - Ahmet K Gündüz
- Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey
| | - Himika Gupta
- Bai Jerbai Wadia Hospital for Children, Mumbai, India
| | - Sanjiv Gupta
- King George's Medical University, Lucknow, India
| | | | - Patrick Hamel
- Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montréal, Quebec, Canada
| | | | | | - Eric D Hansen
- John A. Moran Eye Center, University of Utah, Salt Lake City
| | - J William Harbour
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
| | | | - Murat Hasanreisoglu
- Department of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
| | - Sadiq Hassan
- Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria
| | - Shadab Hassan
- Department of Pediatric Ophthalmology and Strabismus, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan
| | | | - Jose Hernandez
- Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú
| | | | - Laila Hessissen
- Pediatric Hematology and Oncology Center, Mohammed V University, Rabat, Morocco
| | - Diriba F Hordofa
- Department of Pediatrics and Child Health, Jimma University Medical Center, Jimma, Ethiopia
| | - Laura C Huang
- Byers Eye Institute, Stanford University, Stanford, California
| | | | - Marlies Hummlen
- Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
| | | | | | - Russo Ida
- Bambino Gesù IRCCS Children's Hospital, Rome, Italy
| | - Vesna R Ilic
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | | | | | - Helen Jenkinson
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | - Xunda Ji
- Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Dong Hyun Jo
- Fight Against Angiogenesis-Related Blindness Laboratory, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
| | | | - William J Johnson
- Storm Eye Institute, Medical University of South Carolina, Charleston
| | - Michael M Jones
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
| | | | - Rolande L Kabore
- Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou, Ouagadougou, Burkina Faso
| | - Swathi Kaliki
- Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India
| | - Abubakar Kalinaki
- Department of Ophthalmology, Makerere University College of Health Sciences Kamplala, Uganda
| | - Mehmet Kantar
- Division of Pediatric Oncology, School of Medicine, Ege University, Izmir, Turkey
| | | | - Tamar Kardava
- Ophthalmology Department, Central Children's Hospital of Georgia, Tbilisi, Georgia
| | - Rejin Kebudi
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Cerrahpaşa Faculty of Medicine and Oncology Institute, Istanbul University, Istanbul, Turkey
| | - Tomas Kepak
- St. Anne's University Hospital Brno, Masaryk University, and International Clinical Research Center/St Anna University Hospital, Brno, Czech Republic
| | | | | | - Hussain A Khaqan
- Department of Ophthalmology, Postgraduate Medical Institute, Ameer-Ud-Din Medical College, Lahore General Hospital, Lahore, Pakistan
| | - Phara Khauv
- Angkor Hospital for Children, Krong Siem Reap, Cambodia
| | - Wajiha J Kheir
- Duke Eye Center, Duke University Hospital, Durham, North Carolina
| | | | - Alireza Khodabande
- Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Zaza Khotenashvili
- Ophthalmology Department, Central Children's Hospital of Georgia, Tbilisi, Georgia
| | - Jonathan W Kim
- Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles
| | - Jeong Hun Kim
- Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Hayyam Kiratli
- Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Tero T Kivelä
- Ocular Oncology Service, Department of Ophthalmology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Artur Klett
- East Tallinn Central Hospital, Tallinn, Estonia
| | | | - Dalia Krivaitiene
- Children's Ophthalmology Department, Children's Hospital of Vilnius, University Hospital Santaros Clinic, Vilnius, Lithuania
| | - Mariana Kruger
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Kittisak Kulvichit
- Vitreo-Retina Research Unit, Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand
| | | | - Alice Kyara
- Muhimbili National Hospital, Dar es Salaam, Tanzania
| | - Eva S Lachmann
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Carol P S Lam
- Hong Kong Eye Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Geoffrey C Lam
- Perth Children's Hospital, University of Western Australia, Perth, Western Australia, Australia
| | - Scott A Larson
- Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City
| | - Slobodanka Latinovic
- Clinical Center of Vojvodina, University Eye Clinic, Eye Research Foundation Vidar-Latinović, Novi Sad, Serbia
| | - Kelly D Laurenti
- Division of Ophthalmology, Feinberg School of Medicine, Northwestern University, and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Bao Han A Le
- John A. Burns School of Medicine, University of Hawaii, Honolulu, and University of Southern California Roski Eye Institute, Los Angeles
| | - Karin Lecuona
- Division of Ophthalmology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | | | - Cairui Li
- Affiliated Hospital of Dali University, Dali City, China
| | - Ben Limbu
- Tilganga Institute of Ophthalmology, Kathmandu, Nepal
| | | | - Juan P López
- Ophthalmology Department, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Robert M Lukamba
- University Clinics of Lubumbashi, University of Lubumbashi, Lubumbashi, Democratic Rrepublic of Congo
| | | | - Sandra Luna-Fineman
- Pediatric Hematology/Oncology/Stem Cell Transplantation, Center for Global Health, Children's Hospital Colorado, University of Colorado, Aurora
| | - Delfitri Lutfi
- Department of Ophthalmology, Dr Soetomo General Hospital, Airlangga University, Surabaya, Indonesia
| | | | - George N Magrath
- Storm Eye Institute, Medical University of South Carolina, Charleston
| | - Amita Mahajan
- Pediatric Hematology-Oncology Unit, Apollo Center for Advanced Pediatrics, Indraprastha Apollo Hospital, New Delhi, India
| | | | - Erika Maka
- Semmelweis University, Budapest, Hungary
| | - Mayuri Makan
- Sekuru Kaguvi Eye Unit, Parirenyatwa Group of Hospitals, Harare, Zimbabwe
| | | | - Chatonda Manda
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | - Nieves Martín Begue
- Department of Pediatric Ophthalmology, Hospital Vall d'Hebron, Barcelona, Spain
| | | | | | | | - Miguel Materin
- Duke Eye Center, Duke University Hospital, Durham, North Carolina
| | | | - Marchelo Matua
- Ruharo Eye Centre, Ruharo Mission Hospital, Mbarara, Uganda
| | - Ismail Mayet
- University of the Witwatersrand, Johannesburg, South Africa
| | | | - John D McKenzie
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia
| | - Aurora Medina-Sanson
- Department of Oncology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Azim Mehrvar
- MAHAK Hematology Oncology Research Center, Mahak Hospital, Tehran, Iran
| | | | | | | | - Marilyn B Mets
- Division of Ophthalmology, Feinberg School of Medicine, Northwestern University, and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Edoardo Midena
- Department of Ophthalmology, University of Padova, Padova, Italy
| | | | | | - Ahmed A Mohamedani
- Department of Pathology, Faculty of Medicine, University of Gezira, Wad Medani, Sudan
| | | | - Annette C Moll
- Department of Ophthalmology, Amsterdam UMC, Amsterdam, the Netherlands
| | | | - Rosa A Morales
- Hospital Infantil Manuel de Jesús Rivera, Managua, Nicaragua
| | - Claude Moreira
- Service d'Oncologie Pédiatrique de l'Hôpital Aristide le Dantec, Dakar, Senegal
| | | | | | - Gerald Msukwa
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | | | | | - Francis L Munier
- Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne, Switzerland
| | - Gabriela Murgoi
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | | | - Kareem O Musa
- Department of Ophthalmology, Lagos University Teaching Hospital, College of Medicine of the University of Lagos, Lagos, Nigeria
| | - Asma Mushtaq
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | - Hamzah Mustak
- Division of Ophthalmology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | | | - Gita Naidu
- University of the Witwatersrand, Johannesburg, South Africa
| | - Akshay Gopinathan Nair
- Aditya Jyot Eye Hospital, Mumbai, India
- Lokmanya Tilak Municipal General Hospital and Medical College, Mumbai, India
| | - Larisa Naumenko
- N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | | | - Yetty M Nency
- Child Health Department, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
| | - Vladimir Neroev
- Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
| | - Hang Ngo
- Ho Chi Minh Eye Hospital, Ho Chi Minh, Vietnam
| | - Rosa M Nieves
- Hospital Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Republic
| | - Marina Nikitovic
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Elizabeth D Nkanga
- Department of Ophthalmology, Calabar Children's Eye Center, University of Calabar Teaching Hospital, Calabar Nigeria
| | - Henry Nkumbe
- Magrabi ICO Cameroon Eye Institute, Yaounde, Cameroon
| | - Murtuza Nuruddin
- Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh
| | | | | | - Ngozi C Oguego
- Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria
| | - Andrzej Olechowski
- Department of Ophthalmology, The Children's Memorial Health Institute, Warsaw, Poland
| | - Scott C N Oliver
- Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora
| | | | - Diego Ossandon
- Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile
| | | | | | - Sally L Painter
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | | | - Luisa Paiva
- National Ophthalmological Institute of Angola, Luanda, Angola
| | - Bikramjit P Pal
- H M Diwan Eye Foundation, and Tata Medical Center, Kolkata, India
| | | | - Ruzanna Papyan
- Department of Oncology, Yerevan State Medical University, and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R. H. Yeolyan, Yerevan, Armenia
| | | | - Manoj Parulekar
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | | | | | - Katarzyna Pawinska-Wasikowska
- Institute of Pediatrics, Jagiellonian University Medical College, Children's University Hospital of Krakow, Krakow, Poland
| | - Jacob Pe'er
- Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
| | | | - Sanja Peric
- University Hospital Center Zagreb, Zagreb, Croatia
| | - Chau T M Pham
- Vietnam National Institute of Ophthalmology, Ha Noi, Vietnam
| | - Remezo Philbert
- Centre Hospitalier Universitaire de Kamenge, Bujumbura, Burundi
| | | | - Pavel Pochop
- Department of Ophthalmology for Children and Adults, Second Faculty of Medicine, Charles University, and Motol University Hospital, Prague, Czech Republic
| | | | - Vladimir G Polyakov
- Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Russian Medical Academy of Postgraduate Education, Moscow, Russia
| | - Manca T Pompe
- University Eye Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia
| | | | - Daphna Prat
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | | | - Ignatius Purwanto
- Sardjito Hospital, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | | | - Seema Qayyum
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | - Jiang Qian
- Department of Ophthalmology, Eye and Ear, Nose, and Throat Hospital of Fudan University, Shanghai, China
| | - Ardizal Rahman
- Ophthalmology Department, Dr M. Djamil General Hospital, Faculty of Medicine, Andalas University, West Sumatra, Indonesia
| | | | | | | | | | | | - Marco A Ramirez-Ortiz
- Department of Ophthalmology, Hospital Infantil de Mexico Federico Gómez, Mexico City, Mexico
| | - Léa Raobela
- Centre Hospitalier Universitaire Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar
| | - Riffat Rashid
- Department of Oculoplasty and Ocular Oncology, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh
| | - M Ashwin Reddy
- The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
| | - Ehud Reich
- Department of Ophthalmology, Davidoff Center for Oncology, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
| | - Lorna A Renner
- School of Medicine and Dentistry, Korle-Bu Teaching Hospital, University of Ghana, Accra, Ghana
| | | | | | | | - Petra Ritter-Sovinz
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - Duangnate Rojanaporn
- Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Livia Romero
- Unidad de Oncologia Ocular Hospital Oncologico Luis Razzetti, Caracas, Venezuela
| | - Soma R Roy
- Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh
| | - Raya H Saab
- Children's Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon
| | - Svetlana Saakyan
- Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
| | - Ahmed H Sabhan
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Mandeep S Sagoo
- NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, and UCL Institute of Ophthalmology and London Retinoblastoma Service, Royal London Hospital, London, United Kingdom
| | - Azza M A Said
- Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Rohit Saiju
- Tilganga Institute of Ophthalmology, Kathmandu, Nepal
| | - Beatriz Salas
- Hospital Dr Manuel Ascencio Villarroel, Cochabamba, Bolivia
| | | | | | | | | | | | | | - Ahad Sedaghat
- Department of Ophthalmology, Rasool Akram Hospital, Tehran, Iran
| | | | - Rachna Seth
- Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
| | - Ankoor S Shah
- Department of Ophthalmology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | - Sadik T Sherief
- Department of Ophthalmology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | | | - Carol L Shields
- Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Sorath Noorani Siddiqui
- Department of Pediatric Ophthalmology and Strabismus, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan
| | - Sidi Sidi Cheikh
- Ophthalmology Department, Nouakchott Medical University, Nouakchott, Mauritania
| | - Sónia Silva
- Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
| | - Arun D Singh
- Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
| | | | - Usha Singh
- Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Penny Singha
- Department of Ophthalmology, Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand
| | - Rita S Sitorus
- Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, and Dr Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
| | - Alison H Skalet
- Casey Eye Institute, Oregon Health & Science University, Portland
| | - Hendrian D Soebagjo
- Department of Ophthalmology, Dr Soetomo General Hospital, Airlangga University, Surabaya, Indonesia
| | | | - Grace Ssali
- Mulago National Referral Hospital, Kampala, Uganda
| | - Andrew W Stacey
- Department of Ophthalmology, University of Washington, Seattle
| | - Sandra E Staffieri
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia
| | - Erin D Stahl
- Children's Mercy Hospital, Kansas City, Missouri
| | - Christina Stathopoulos
- Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne, Switzerland
| | - Branka Stirn Kranjc
- University Eye Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia
| | - David K Stones
- Department of Paediatrics and Child Health, University of the Free State, Bloemfontein, South Africa
| | | | | | - Sadia Sultana
- Department of Oculoplasty and Ocular Oncology, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh
| | - Xiantao Sun
- Henan Children's Hospital, Affiliated Children's Hospital of Zhengzhou University, Zhengzhou, China
| | - Meryl Sundy
- Casey Eye Institute, Oregon Health & Science University, Portland
| | - Rosanne Superstein
- Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montréal, Quebec, Canada
| | - Eddy Supriyadi
- Sardjito Hospital, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | | | - Shigenobu Suzuki
- Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Karel Svojgr
- Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
| | | | - Gevorg Tamamyan
- Department of Oncology, Yerevan State Medical University, and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R. H. Yeolyan, Yerevan, Armenia
| | - Deborah Tan
- Singapore National Eye Center, Singapore, Singapore
| | - Alketa Tandili
- University Hospital Center Mother Theresa, Tirana, Albania
| | | | - Maryam Tashvighi
- MAHAK Hematology Oncology Research Center, Mahak Hospital, Tehran, Iran
| | | | - Edi S Tehuteru
- National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia
| | - Luiz F Teixeira
- Pediatric Oncology Institute, Federal University of São Paulo, São Paulo, Brazil
- Ophthalmology Department, Federal University of São Paulo, São Paulo, Brazil
| | - Kok Hoi Teh
- Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
| | | | - Helen Toledano
- Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Doan L Trang
- Vietnam National Institute of Ophthalmology, Ha Noi, Vietnam
| | - Fousseyni Traoré
- Pediatric Oncology Service, Gabriel Toure Hospital, Bamako, Mali
| | | | - Samuray Tuncer
- Department of Ophthalmology, Faculty of Medicine, Ocular Oncology Service, Istanbul University, Istanbul, Turkey
| | | | - Ali B Umar
- Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria
| | - Emel Unal
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Ankara University, Ankara, Turkey
| | | | - Steen F Urbak
- Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark
| | - Tatiana L Ushakova
- Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Russian Medical Academy of Postgraduate Education, Moscow, Russia
| | | | | | | | - Adisai Varadisai
- Vitreo-Retina Research Unit, Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand
| | | | | | - Nevyana V Veleva-Krasteva
- Eye Clinic, Department of Ophthalmology, University Hospital Alexandrovska, Medical University, Sofia, Sofia, Bulgaria
| | | | - Andi A Victor
- Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, and Dr Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
| | | | | | - Vicktoria Vishnevskia-Dai
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | - Keith Waddell
- Ruharo Eye Centre, Ruharo Mission Hospital, Mbarara, Uganda
| | | | | | - Yi-Zhuo Wang
- Department of Paediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China
| | - Avery Weiss
- Department of Ophthalmology, University of Washington, Seattle
| | - Matthew W Wilson
- Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee
| | - Amelia D C Wime
- National Ophthalmological Institute of Angola, Luanda, Angola
| | | | | | | | - Phanthipha Wongwai
- Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Daoman Xiang
- Department of Pediatric Ophthalmology, Guangzhou Children's Hospital and Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China
| | | | - Jason C Yam
- Hong Kong Eye Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Huasheng Yang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | - Jenny M Yanga
- Service d'Ophtalmologie, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of Congo
| | | | - Vera A Yarovaya
- S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia
| | - Andrey A Yarovoy
- S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia
| | - Huijing Ye
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | | | - Putu Yuliawati
- Department of Ophthalmology, Faculty of Medicine, Udayana University, Sanglah Eye Hospital, Bali, Indonesia
| | | | - Ekhtelbenina Zein
- Assistante Hospitalo Universitaire, Faculte de Medecine de Nouakchott Medecin Oncopediatre, Center National d'Oncologie, Nouakchott, Mauritania
| | - Chengyue Zhang
- Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China
| | - Yi Zhang
- Department of Paediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China
| | - Junyang Zhao
- Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China
| | - Xiaoyu Zheng
- Department of Ophthalmology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | | | - Nida Zia
- The Indus Hospital, Karachi, Pakistan
| | - Othman A O Ziko
- Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Marcia Zondervan
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Richard Bowman
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
- Ophthalmology Department, Great Ormond Street Hospital, London, United Kingdom
| |
Collapse
|
16
|
Doz F, Geoerger B, DuBois SG, Grilley-Olson JE, van Tilburg CM, Italiano A, Lissat A, Jin Kang H, Tahara M, Boni V, Perreault S, Capra M, Nanda S, Brega N, Holynskyj A, Ziegler DS, Hong DS, Hyman DM, Drilon A. RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz175.968] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
TRK fusions are oncogenic drivers of a variety of tumors, many of which can involve the central nervous system (CNS). Larotrectinib is a selective TRK inhibitor FDA-approved for the treatment of TRK fusion cancers (Drilon et al., NEJM 2018). Here we report on the clinical activity of larotrectinib in an expanded set of TRK fusion-positive primary CNS tumors.
METHODS
Patients with primary CNS tumors harboring a TRK fusion treated with larotrectinib on two clinical trials (NCT02637687 and NCT02576431) were identified by local molecular testing. Larotrectinib was administered until disease progression, withdrawal, or unacceptable toxicity. Disease status was investigator assessed (RANO). Data cutoff: February 19, 2019.
RESULTS
18 patients with various histological types of glial tumors (11 high-grade, 4 low-grade, 3 unknown) were identified. The patients had gene fusions involving NTRK2 (n=13), NTRK1 (n=2) and NTRK3 (n=2); one was not determined. Median age was 10 years (range 1–79); 14 patients were pediatric (< 18). In 14 evaluable patients, the objective response rate was 36% (2 CR, 3 PR), with responses seen in high- and low-grade disease and across histologies. Nine patients had SD. The 24-week disease control rate was 71%. The duration of treatment ranged from 0.03+ to 16.6+ months. One patient (3.7 years old) with glioblastoma progressed after 5.5 months on larotrectinib. Sequencing revealed a solvent front mutation and the patient was subsequently enrolled in compassionate use protocol for BAY2731954 (formerly known as LOXO-195).
CONCLUSION
Larotrectinib is active in patients with TRK fusion cancer with intracranial disease. Confirmed responses and durable disease control were seen in primary CNS tumors of various grades and histologies. These results further support expanded testing for NTRK gene fusions in patients with primary CNS tumors.
Collapse
Affiliation(s)
- Francois Doz
- Institut Curie and Paris University, Paris, France
| | | | - Steven G DuBois
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
| | | | | | | | | | - Hyoung Jin Kang
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Makoto Tahara
- National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | | | | | | | | | | | - David S Hong
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David M Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | |
Collapse
|
17
|
Ziegler D, Doz F, Geoerger B, Dubois S, Grilley-Olson J, van Tilburg C, Italiano A, Lissat A, Kang JH, Tahara M, Boni V, Perreault S, Capra M, Nanda S, Brega N, Holynskyj A, Hong D, Hyman D, Drilon A. Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Quinlan CS, Capra M, Dempsey M. Paediatric malignant melanoma in Ireland: A population study and review of the literature. J Plast Reconstr Aesthet Surg 2019; 72:1388-1395. [PMID: 31101426 DOI: 10.1016/j.bjps.2019.03.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 11/18/2018] [Accepted: 03/30/2019] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Malignant melanoma is increasing in frequency worldwide; however, this disease is rare in children. As large-scale studies on paediatric melanoma are lacking, management is currently often based upon the understanding of the disease process in adults. The aim of this study was to characterise cases of paediatric melanoma diagnosed in the Republic of Ireland over a 21-year period. METHODS This was a retrospective, multicentre study using national data provided by the National Cancer Registry of Ireland and individual practitioners. RESULTS Twenty-four cases of melanoma treated in 11 different centres were included in the study. The median patient age at diagnosis was 15 years. The majority of cases arose on the limbs. The median Breslow thickness in patients of the pre-pubertal age group was 8.25 mm, while in children more than 13 years, it was 1.65 mm. Eight patients had disease recurrence and five patients died. CONCLUSION The diagnosis of melanoma remains rare in children. This study contributes to our current understanding of malignant melanoma in paediatric patients; however, further investigation of the disease characteristics in this group is necessary to achieve optimal management of these cases and therefore improve outcomes.
Collapse
Affiliation(s)
- Christine S Quinlan
- Department of Plastic and Reconstructive Surgery, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland.
| | - Michael Capra
- Department of Paediatric Oncology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| | - Marlese Dempsey
- Department of Plastic and Reconstructive Surgery, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| |
Collapse
|
19
|
Hyman D, Kummar S, Farago A, Geoerger B, Mau-Sorensen M, Taylor M, Garralda E, Nagasubramanian R, Natheson M, Song L, Capra M, Jorgensen M, Ho A, Shukla N, Smith S, Huang X, Tuch B, Ku N, Laetsch TW, Drilon A, Hong D. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-ct127] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Abstract
Background: Larotrectinib, a selective TRKi, is now FDA approved for pediatric and adult TRK-fusion solid tumors, regardless of tumor origin. Emergent TRK kinase mutations are a common mechanism of resistance to TRKis. LOXO-195, a selective TRKi, was developed to maintain potency against multiple TRK kinase domain mutations.
Methods: Patients (pts) received LOXO-195 via a Phase I study (NCT03215511, n=20) or FDA expanded access single patient protocol (SPP, n=11). Eligible pts were ≥4-weeks old with a locally identified TRK fusion and had progressed or were intolerant to at least 1 priorTRKi. Parallel 3+3 dose escalations were pursued in adults and children, with intra-patient dose escalation permitted based on tolerance and pharmacokinetics. Pts aged <12 received BSA-adjusted doses.
Results: As of 03-DEC-2018, a total of 31 TRK-fusion pts (7 children, 24 adults) with 11 cancer types had been treated. Median duration on last prior TRKi was 9.5 months (range, 2-30). In the Phase 1, doses of 32 mg QD to 150mg BID were explored, and TEAEs (all grades/cause, in >3 pts) were dizziness/ataxia (65%), nausea/vomiting (50%), anemia (30%), myalgia, abdominal pain, fatigue, & lymphopenia (all 20%). Five Phase I pts (all adults) had DLTs: ataxia/dizziness (4), and ataxia/vomiting (1). For the SPPs: 1 pt dose-reduced and none discontinued for a TEAE. Cmax at doses ≥50 mg exceeded the predicted IC50 for TRK kinase mutations. Pretreatment tissue and/or plasma, as available, defined TRK kinase mutation status. Preliminary efficacy overall, and by TRK kinase mutation status, is shown in the Table.
Discussion: LOXO-195 had preliminary efficacy in pts with resistance to prior TRKi mediated by TRK kinase mutations. The subset of pts who develop TRK-independent resistance are unlikely to benefit from LOXO-195. Dose selection is ongoing in both children and adults.
Confirmed best overall response, all dose levels, investigator assessed per RECIST 1.1 (n=29≠)Patient CohortTotal Patients,nCR/PR, nStable Disease, nPD, nNon- evaluable, †nORRTRK Kinase Mutation20963245% (9/20)Solvent Front14742150% (7/14)Gatekeeper4111125% (1/4)xDFG2110050% (1/2)Identified bypass300210% (0/3)Other/ Unknown*61#31117% (1/6)Overall291096434% (10/29)≠ 2 pts still on study drug and awaiting 1st response assessment not included in Table.† 4 pts non-evaluable: 1 discontinued drug for unrelated new cancer diagnosis <28 days after start of study drug and 3 withdrew within 14 days of study drug start.* Includes 1 pt with no identified TRK kinase resistance mutationor bypass alteration# and 5 pts who could not be tested.# Pt intolerant but not resistant to prior TRKi
Citation Format: David Hyman, Shivaani Kummar, Anna Farago, Birgit Geoerger, Morten Mau-Sorensen, Matthew Taylor, Elena Garralda, Ramamoorthy Nagasubramanian, Michael Natheson, Lucy Song, Michael Capra, Mette Jorgensen, Alan Ho, Neerav Shukla, Steve Smith, Xin Huang, Brian Tuch, Nora Ku, Theodore W. Laetsch, Alexander Drilon, David Hong. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT127.
Collapse
Affiliation(s)
- David Hyman
- 1Mem. Sloan Kettering Cancer Ctr., New York, NY
| | | | | | | | | | | | | | | | | | - Lucy Song
- 10Kaiser Permanente Medical Center, Santa Clara, CA
| | | | - Mette Jorgensen
- 12Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
| | - Alan Ho
- 1Mem. Sloan Kettering Cancer Ctr., New York, NY
| | | | | | - Xin Huang
- 13Loxo Oncology, South San Francisco, CA
| | - Brian Tuch
- 13Loxo Oncology, South San Francisco, CA
| | - Nora Ku
- 13Loxo Oncology, South San Francisco, CA
| | - Theodore W. Laetsch
- 14University of Texas Southwestern Medical Center/Children’s Health, Dallas, TX
| | | | - David Hong
- 15MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
20
|
Irvine I, Walshe T, Capra M, Hayes R. Scurvy: an unusual complication of paediatric cancer treatment. Skeletal Radiol 2019; 48:995-998. [PMID: 30374635 DOI: 10.1007/s00256-018-3103-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2018] [Revised: 10/13/2018] [Accepted: 10/16/2018] [Indexed: 02/02/2023]
Abstract
Scurvy is a disease that is rarely encountered in modern medicine. A condition that was classically associated with sailors, its incidence has decreased dramatically since the discovery of its association with vitamin C deficiency. We present the case of a 2-year-old boy, whose treatment for neuroblastoma was complicated by gastrointestinal disease, which necessitated enteral feeding. While still undergoing treatment, he started to complain about increasing pain in his lower limbs, which appeared to be markedly tender on palpation. Radiographic findings suggested a diagnosis of scurvy, which was subsequently confirmed on serum biochemistry. This was an unexpected finding, as the child had been receiving adequate vitamin C in his enteral feeds. However, his absorption had become severely impaired due to pseudomembranous gastritis and enteritis, leading to his deficient state. He significantly improved after intravenous ascorbic acid replacement and demonstrated a full recovery, both clinically and radiologically. This case highlights the importance of considering scurvy in the differential diagnosis for at-risk patients. Early recognition can facilitate the simple treatment of this potentially serious condition.
Collapse
Affiliation(s)
- Iain Irvine
- Department of Radiology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland.
| | - Triona Walshe
- Department of Radiology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| | - Michael Capra
- Department of Oncology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| | - Roisin Hayes
- Department of Radiology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| |
Collapse
|
21
|
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019; 109:36-50. [PMID: 30685685 PMCID: PMC6506906 DOI: 10.1016/j.ejca.2018.11.027] [Citation(s) in RCA: 305] [Impact Index Per Article: 61.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 11/12/2018] [Accepted: 11/16/2018] [Indexed: 11/11/2022]
Abstract
Background High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. Methods Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients. Results For all registered patients at a median follow-up of 54 months (interquartile range: 38–73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57–61%) and 54% (95% CI: 52–56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95–2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38–2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10–2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33–0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52–0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77–81%) and 71% (95% CI: 68–73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76–2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome. Conclusions In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider. Osteosarcoma is a rare disease, and treatment can only improve with international collaboration. We have assembled prospectively collected data from treatments of all the patients in the intercontinental European and American Osteosarcoma Study-1 protocol. These consistently treated patients provided a strong data set for reporting survival outcomes and reporting on prognostic factors. The trial reaffirms known prognostic factors, and the most adverse factors were metastases and tumours in the axial skeleton. Owing to the large numbers of patients registered, light is shed on some additional factors to be considered. Around seven in ten patients were still alive five years after diagnosis.
Collapse
Affiliation(s)
- Sigbjørn Smeland
- SSG Oslo University Hospital and Scandinavian Sarcoma Group and Institute for Clinical Medicine, University of Oslo, Norway.
| | | | | | - Mark Bernstein
- COG IWK Health Center, Dalhousie University, Halifax, NS, Canada
| | | | | | - Richard Gorlick
- COG the University of Texas M D Anderson Cancer Center, Houston, TX, USA
| | | | | | | | - Imre Antal
- COSS Semmelweis Egyetem Budapest, Budapest, Hungary
| | | | - Ken L B Brown
- COG University of British Columbia, Vancouver, BC, Canada
| | | | - Gabriele Calaminus
- QLCC Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Bonn, Bonn, Germany
| | | | | | | | - Adrienne M Flanagan
- EOI Royal National Orthopaedic Hospital, Stanmore; Cancer Institute, University College London, London, UK
| | | | | | - Hans Gelderblom
- EOI Leiden University Medical Center, Leiden, the Netherlands
| | - Robert Goldsby
- COG UCSF Medical Center-Mission Bay, Pediatric Oncology, San Francisco, CA, USA
| | | | | | | | | | | | | | | | - Thomas Kühne
- COSS Universitätsspital Basel, Basel, Switzerland
| | - Leo Kager
- COSS St. Anna Kinderspital /CCRI, Wien, Austria
| | | | | | - Susanna Lang
- COSS Medizinische Universität Wien, Vienna, Austria
| | - Ching C Lau
- COG Baylor College of Medicine, Houston, TX, USA
| | | | - Stephen L Lessnick
- COG Nationwide Children's Hospital and the Ohio State University, Columbus, OH, USA
| | - Leo Mascarenhas
- COG Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | - Paul A Meyers
- COG Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Raj Nagarajan
- COG Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - R Lor Randall
- COG Primary Childrens Hospital, The University of Utah, Salt Lake City, UT, USA
| | | | | | | | - Cindy L Schwartz
- COG the University of Texas M D Anderson Cancer Center, Houston, TX, USA
| | | | - Lisa Teot
- COG Boston Children's Hospital, Boston, MA, USA
| | | | | | - Neyssa Marina
- COG Five Prime Therapeutics, Inc South San Francisco, CA, USA
| |
Collapse
|
22
|
Carroll C, Clinton F, Smith A, Fox A, Capra M, Pears J, Owens C. Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma. Pediatr Blood Cancer 2018; 65:e27386. [PMID: 30230225 DOI: 10.1002/pbc.27386] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 07/03/2018] [Accepted: 07/05/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND High-risk neuroblastoma (HR NBL) treatment requires intensive induction chemotherapy. The profoundly emetogenic agents used can compromise nutritional status. Our institution introduced a new antiemetic guideline in 2010 incorporating regular dexamethasone, in addition to ondansetron, for all highly emetogenic protocols. PROCEDURE A retrospective comparative review of pediatric patients diagnosed with HR NBL who received rapid COJEC induction chemotherapy as per HR-SIOPEN NBL trial. Prophylactic antiemetics were prescribed regardless of chemotherapy emetogenicity in group A (2004-2010) but for defined time periods considering chemotherapy emetogenicity in group B (2010-2017). RESULTS Sixty-three children were eligible for inclusion (median age, 31 months; range, 1-88 months). Group A had more episodes of emesis than group B (189 vs. 116, P < 0.0001). There was a significant difference in weight-for-age Z score change between the groups by induction end (P = 0.0027). Four children (13%) in group A lost >10% body weight versus none in group B. Nutrition support (NS) was utilized by 29 children (94%) in group A and 22 children (69%) in group B. Group A had a median of 3 (range, 1-7) admissions for febrile neutropenia (FN) versus a median of 1.5 (range, 0-4) for group B (P = 0.003) during induction. CONCLUSION The review of our guidelines led to reduced emesis frequency for group B. They also required less NS, followed expected growth trajectories more closely and had fewer FN admissions. We propose that this may have occurred due to better emesis control resulting in improved nutritional status and associated enhanced immune function.
Collapse
Affiliation(s)
- Catherine Carroll
- Department of Nutrition and Dietetics, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Frieda Clinton
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Aisling Smith
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Aine Fox
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Michael Capra
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Jane Pears
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| | - Cormac Owens
- Department of Haematology/Oncology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
| |
Collapse
|
23
|
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 2018; 378:2376-2385. [PMID: 29924955 PMCID: PMC6117111 DOI: 10.1056/nejmoa1801109] [Citation(s) in RCA: 176] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Cisplatin chemotherapy and surgery are effective treatments for children with standard-risk hepatoblastoma but may cause considerable and irreversible hearing loss. This trial compared cisplatin with cisplatin plus delayed administration of sodium thiosulfate, aiming to reduce the incidence and severity of cisplatin-related ototoxic effects without jeopardizing overall and event-free survival. METHODS We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses. The primary end point was the absolute hearing threshold, as measured by pure-tone audiometry, at a minimum age of 3.5 years. Hearing loss was assessed according to the Brock grade (on a scale from 0 to 4, with higher grades indicating greater hearing loss). The main secondary end points were overall survival and event-free survival at 3 years. RESULTS A total of 109 children were randomly assigned to receive cisplatin plus sodium thiosulfate (57 children) or cisplatin alone (52) and could be evaluated. Sodium thiosulfate was associated with few high-grade toxic effects. The absolute hearing threshold was assessed in 101 children. Hearing loss of grade 1 or higher occurred in 18 of 55 children (33%) in the cisplatin-sodium thiosulfate group, as compared with 29 of 46 (63%) in the cisplatin-alone group, indicating a 48% lower incidence of hearing loss in the cisplatin-sodium thiosulfate group (relative risk, 0.52; 95% confidence interval [CI], 0.33 to 0.81; P=0.002). At a median of 52 months of follow-up, the 3-year rates of event-free survival were 82% (95% CI, 69 to 90) in the cisplatin-sodium thiosulfate group and 79% (95% CI, 65 to 88) in the cisplatin-alone group, and the 3-year rates of overall survival were 98% (95% CI, 88 to 100) and 92% (95% CI, 81 to 97), respectively. CONCLUSIONS The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival. (Funded by Cancer Research UK and others; SIOPEL 6 ClinicalTrials.gov number, NCT00652132 ; EudraCT number, 2007-002402-21 .).
Collapse
Affiliation(s)
- Penelope R Brock
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Rudolf Maibach
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Margaret Childs
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Kaukab Rajput
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Derek Roebuck
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Michael J Sullivan
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Véronique Laithier
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Milind Ronghe
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Patrizia Dall'Igna
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Eiso Hiyama
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Bénédicte Brichard
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Jane Skeen
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - M Elena Mateos
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Michael Capra
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Arun A Rangaswami
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Marc Ansari
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Catherine Rechnitzer
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Gareth J Veal
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Anna Covezzoli
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Laurence Brugières
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Giorgio Perilongo
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Piotr Czauderna
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Bruce Morland
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| | - Edward A Neuwelt
- From Great Ormond Street Hospital, London (P.R.B., K.R., D.R.), Nottingham Clinical Trials Unit, Nottingham (M. Childs), Royal Hospital for Sick Children, Glasgow (M.R.), Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne (G.J.V.), and University of Birmingham, Birmingham (B.M.) - all in the United Kingdom; International Breast Cancer Study Group, Bern (R.M.), and Hôpital Universitaire de Genève, Geneva (M.A.) - both in Switzerland; University of Melbourne, Melbourne, VIC, Australia (M.J.S.); University of Otago, Christchurch (M.J.S.), and Starship Children's Hospital, Auckland (J.S.) - both in New Zealand; Centre Hospitalier Universitaire, Besançon (V.L.), and Institut de Cancerologie Gustave Roussy, Villejuif (L.B.) - both in France; University of Padua, Padua (P.D., G.P.), and Consorzio Interuniversitario (CINECA), Bologna (A.C.) - both in Italy; Hiroshima University, Hiroshima, Japan (E.H.); Cliniques Universitaires Saint Luc, Brussels (B.B.); University Hospital Reina Sofia, Cordoba, Spain (M.E.M.); Our Lady's Children's Hospital, Dublin (M. Capra); Stanford University Medical Center, Palo Alto, CA (A.A.R.); University Hospital Rigshospitalet, Copenhagen (C.R.); Medical University of Gdansk, Gdansk, Poland (P.C.); and Oregon Health and Science University, Portland (E.A.N.)
| |
Collapse
|
24
|
Kilday JP, Caldarelli M, Massimi L, Chen RHH, Lee YY, Liang ML, Parkes J, Naiker T, van Veelen ML, Michiels E, Mallucci C, Pettorini B, Meijer L, Dorfer C, Czech T, Diezi M, Schouten-van Meeteren AYN, Holm S, Gustavsson B, Benesch M, Müller HL, Hoffmann A, Rutkowski S, Flitsch J, Escherich G, Grotzer M, Spoudeas HA, Azquikina K, Capra M, Jiménez-Guerra R, MacDonald P, Johnston DL, Dvir R, Constantini S, Kuo MF, Yang SH, Bartels U. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2018; 19:1398-1407. [PMID: 28499018 DOI: 10.1093/neuonc/nox056] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha. Methods European Société Internationale d'Oncologie Pédiatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events, and outcomes were obtained. Progression was clinical or radiological (cyst reaccumulation, novel cysts, or solid growth). Results Fifty-six children (median age, 6.3 y) from 21 international centers were identified. Median follow-up from diagnosis was 5.1 years (0.3-17.7 y). Lesions were cystic (n = 22; 39%) or cystic/solid (n = 34; 61%). Previous progression was treated in 43 (77%) patients before interferon use. In such cases, further progression was delayed by intracystic interferon compared with the preceding therapy for cystic lesions (P = 0.0005). Few significant attributable side effects were reported. Progression post interferon occurred in 42 patients (median 14 mo; 0-8 y), while the estimated median time to definitive therapy post interferon was 5.8 (1.8-9.7) years. Conclusions Intracystic interferon-alpha can delay disease progression and potentially offer a protracted time to definitive surgery or radiotherapy in pediatric cystic craniopharyngioma, yet demonstrates a favorable toxicity profile compared with other therapeutic modalities-important factors for this developing age group. A prospective, randomized international clinical trial assessment is warranted.
Collapse
Affiliation(s)
- John-Paul Kilday
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Massimo Caldarelli
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Luca Massimi
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Robert Hsin-Hung Chen
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Yi Yen Lee
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Muh-Lii Liang
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Jeanette Parkes
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Thuran Naiker
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Marie-Lise van Veelen
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Erna Michiels
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Conor Mallucci
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Benedetta Pettorini
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Lisethe Meijer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Christian Dorfer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Thomas Czech
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Manuel Diezi
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Antoinette Y N Schouten-van Meeteren
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Stefan Holm
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Bengt Gustavsson
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Martin Benesch
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Hermann L Müller
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Anika Hoffmann
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Stefan Rutkowski
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Joerg Flitsch
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Gabriele Escherich
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Michael Grotzer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Helen A Spoudeas
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Kristian Azquikina
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Michael Capra
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Rolando Jiménez-Guerra
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Patrick MacDonald
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Donna L Johnston
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Rina Dvir
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Shlomi Constantini
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Meng-Fai Kuo
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Shih-Hung Yang
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Ute Bartels
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| |
Collapse
|
25
|
Lee KA, O'Sullivan C, Daly P, Pears J, Owens C, Timmermann B, Ares C, Combs SE, Indelicato D, Capra M. Proton therapy in paediatric oncology: an Irish perspective. Ir J Med Sci 2016; 186:577-582. [PMID: 27744643 DOI: 10.1007/s11845-016-1520-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 10/11/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND Proton therapy (PT) is a radiotherapy treatment modality that uses protons, rather than conventional photons. PT is often used in paediatric oncology due to its reported capability to reduce acute and late adverse treatment effects. As PT is unavailable in Ireland, patients are referred abroad for treatment. AIMS To: (1) produce a descriptive study of Irish children referred abroad for PT, and (2) discuss the case for PT in general. METHODS A retrospective review of all children referred for PT before October 2015 was performed. Information was gathered regarding demographics, diagnosis, referral timeline, adverse effects attributable to PT, current status and cost. A review of the relevant literature was performed. RESULTS Seventeen children treated in Ireland have been referred abroad for PT. The largest number was in the 0-4 year old group. At initial diagnosis the median age was 4.8 years. The average cost per child was €37,312. Two patients suffered disease relapse. Four have encountered PT-related adverse effects. CONCLUSION Despite the fact that >100,000 patients worldwide have been treated with PT, the level of published evidence to support superiority over conventional treatment remains low. It is debated that randomised control trials in this area would be inconsistent with the principle of clinical equipoise. In contrast, there is a call for level 1 evidence to justify drastic changes in patient care, particularly in light of recent reports of unexpected toxicities. In time, careful evaluation, follow-up and clinical trials will likely support the preferential use of PT in children.
Collapse
Affiliation(s)
- K A Lee
- St. Luke's Radiation Oncology Network, Radiation Oncology, Dublin, Ireland. .,Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland.
| | - C O'Sullivan
- St. Luke's Radiation Oncology Network, Radiation Oncology, Dublin, Ireland.,Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland
| | - P Daly
- St. Luke's Radiation Oncology Network, Radiation Oncology, Dublin, Ireland.,Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland
| | - J Pears
- Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland
| | - C Owens
- Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland
| | - B Timmermann
- Department of Radiation Sciences (DRS), Institute of Innovative Radiotherapy (iRT), HelmholtzZentrum Munchen (HMGU) Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.,Particle Therapy Department, West German Proton Therapy Centre Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - C Ares
- Paul Scherrer Institute, Center for Proton Therapy, 5232, Villigen Psi, Switzerland.,Hopitaux Universitaires de Geneve, Service de Radio-oncologie, Geneve, GE, Switzerland
| | - S E Combs
- Universitätsklinikum Heidelberg, Klinik für Radioonkologie und Strahlentherapie Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.,Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany
| | - D Indelicato
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, 32610-0385, USA
| | - M Capra
- Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland
| |
Collapse
|
26
|
Cullinan N, Caird J, Capra M, Pears J, Owens C, Crimmins D. LG-48PAEDIATRIC LOW GRADE GLIOMAS - IMPACT OF GROSS TOTAL RESECTION IN A SINGLE CENTRE COHORT. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now075.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Cullinan N, Cryan J, O'Sullivan C, Daly P, Farrell M, Capra M, Pears J, Owens C. CR-13RADIATION-INDUCED GLIOBLASTOMA MULTIFORME WITHIN 4 YEARS OF CRANIAL IRRADIATION FOR PAEDIATRIC CRANIOPHARYNGIOMA - CASE REPORT AND REVIEW OF THE LITERATURE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now068.13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Javadpour M, Giva S, Costigan C, Caird J, Crimmins D, Capra M, Pears J, Owens C, Brosnahan D, O'Sullivan C, Cody D. CR-22EARLY OUTCOMES OF ENDOSCOPIC EXTENDED TRANSSPHENOIDAL SURGERY FOR CRANIOPHARYNGIOMAS IN CHILDREN. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now068.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Kilday J, Massimi L, Caldarelli M, Lee Y, Chen H, Yiang M, Parkes J, Naiker T, van Veelen M, Michiels E, Pettorini B, Mallucci C, Meijer L, Dorfer C, Czech T, Diezi M, van Schouten N, Holm S, Gustavsson B, Benesch M, Hoffman A, Muller H, Escherich G, Flitsch J, Rutkowski S, Grotzer M, Spoudeas H, Capra M, Jimenez-Guerra R, MacDonald P, Johnston D, Dvir R, Constantini S, Kuo M, Yang S, Bartels U. CR-12INTRACYSTIC INTERFERON-ALPHA IN PAEDIATRIC CRANIOPHARYNGIOMA PATIENTS: AN INTERNATIONAL MULTI-CENTRE ASSESSMENT ON BEHALF OF SIOP-E AND ISPN. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now068.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
30
|
Lee K, O'Sullivan C, Capra M. EP-1418: Proton therapy in paediatric oncology – An Irish perspective. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32668-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
31
|
Mahamdallie SS, Hanks S, Karlin KL, Zachariou A, Perdeaux ER, Ruark E, Shaw CA, Renwick A, Ramsay E, Yost S, Elliott A, Birch J, Capra M, Gray J, Hale J, Kingston J, Levitt G, McLean T, Sheridan E, Renwick A, Seal S, Stiller C, Sebire N, Westbrook TF, Rahman N. Erratum: Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor. Nat Genet 2016; 48:473. [DOI: 10.1038/ng0329-473d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
32
|
Mahamdallie SS, Hanks S, Karlin KL, Zachariou A, Perdeaux ER, Ruark E, Shaw CA, Renwick A, Ramsay E, Yost S, Elliott A, Birch J, Capra M, Gray J, Hale J, Kingston J, Levitt G, McLean T, Sheridan E, Renwick A, Seal S, Stiller C, Sebire N, Westbrook TF, Rahman N. Mutations in the transcriptional repressor REST predispose to Wilms tumor. Nat Genet 2015; 47:1471-4. [PMID: 26551668 DOI: 10.1038/ng.3440] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 10/14/2015] [Indexed: 02/08/2023]
Abstract
Wilms tumor is the most common childhood renal cancer. To identify mutations that predispose to Wilms tumor, we are conducting exome sequencing studies. Here we describe 11 different inactivating mutations in the REST gene (encoding RE1-silencing transcription factor) in four familial Wilms tumor pedigrees and nine non-familial cases. Notably, no similar mutations were identified in the ICR1000 control series (13/558 versus 0/993; P < 0.0001) or in the ExAC series (13/558 versus 0/61,312; P < 0.0001). We identified a second mutational event in two tumors, suggesting that REST may act as a tumor-suppressor gene in Wilms tumor pathogenesis. REST is a zinc-finger transcription factor that functions in cellular differentiation and embryonic development. Notably, ten of 11 mutations clustered within the portion of REST encoding the DNA-binding domain, and functional analyses showed that these mutations compromise REST transcriptional repression. These data establish REST as a Wilms tumor predisposition gene accounting for ∼2% of Wilms tumor.
Collapse
Affiliation(s)
| | - Sandra Hanks
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Kristen L Karlin
- Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.,Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Anna Zachariou
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | | | - Elise Ruark
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Chad A Shaw
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Alexander Renwick
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Emma Ramsay
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Shawn Yost
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Anna Elliott
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Jillian Birch
- Paediatric and Familial Cancer Research Group, University of Manchester, Manchester, UK
| | - Michael Capra
- Haematology Oncology-National Paediatric Centre, Our Lady's Children's Hospital, Dublin, Ireland
| | - Juliet Gray
- Cancer Sciences Unit, University of Southampton, Southampton, UK
| | - Juliet Hale
- Department of Paediatric and Adolescent Haematology and Oncology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
| | - Judith Kingston
- Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK
| | - Gill Levitt
- Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK
| | - Thomas McLean
- Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - Eamonn Sheridan
- Yorkshire Clinical Genetics Service, Chapel Allerton Hospital, Leeds, UK
| | - Anthony Renwick
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Sheila Seal
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | | | - Neil Sebire
- Department of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK
| | - Thomas F Westbrook
- Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.,Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Nazneen Rahman
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.,Cancer Genetics Unit, Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London, UK
| |
Collapse
|
33
|
Brock PR, Maibach R, Childs M, Rajput K, Neuwelt EA, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Lockwood L, dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Fabre M, Rangaswami AA, Capra M, Czauderna P, Morland B. Anti-tumor efficacy in SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.10039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Rudolf Maibach
- International Breast Cancer Study Group, Bern, Switzerland
| | | | - Kaukab Rajput
- Great Ormond Street Hospital for Sick Children, London, United Kingdom
| | | | - Derek Roebuck
- Great Ormond Street Hospital, London, United Kingdom
| | | | | | - Milind Ronghe
- Royal Hospital for Sick Children, Glasgow, United Kingdom
| | | | - Patrizia dall'Igna
- Paediatric Haematology Oncology Division, University of Padova, Padova, Italy
| | | | | | - Jane Skeen
- Starship Children's Hospital, Auckland, New Zealand
| | | | - Monique Fabre
- Institut de Cancerologie Gustave Roussy, Villejuif, France
| | | | - Michael Capra
- Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | | | - Bruce Morland
- Birmingham Children's Hospital, Birmingham, United Kingdom
| |
Collapse
|
34
|
Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PCW, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2014; 26:407-14. [PMID: 25421877 PMCID: PMC4304379 DOI: 10.1093/annonc/mdu526] [Citation(s) in RCA: 193] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. PATIENTS AND METHODS Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken. RESULTS Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen. CONCLUSIONS New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327.
Collapse
Affiliation(s)
- J S Whelan
- Department of Oncology, University College Hospital, London, UK
| | - S S Bielack
- Cooperative Osteosarcoma Study Group (COSS), Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
| | - N Marina
- Stanford University Medical Center, Pediatric Hematology/Oncology, Palo Alto, USA
| | - S Smeland
- Division of Cancer, Surgery and Transplantation, and Scandinavian Sarcoma Group, Oslo University Hospital, Oslo Institute for Clinical Medicine, University of Oslo, Oslo, Norway
| | - G Jovic
- Medical Research Council Clinical Trials Unit at University College London, London, UK
| | - J M Hook
- Medical Research Council Clinical Trials Unit at University College London, London, UK
| | - M Krailo
- Children's Oncology Group, Arcadia, USA
| | - J Anninga
- Department of Pediatrics and Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | | | - T Böhling
- University of Helsinki and HUSLAB, Helsinki, Finland
| | - G Calaminus
- University Hospital of Muenster, Muenster, Germany
| | - M Capra
- Our Lady's Children's Hospital, Dublin, Ireland
| | - C Deffenbaugh
- Lucile Salter Packard Childrens Hospital Stanford, Palo Alto, USA
| | - C Dhooge
- University Hospital Ghent, Gent, Belgium
| | - M Eriksson
- Skane University Hospital, Lund University, Lund, Sweden
| | - A M Flanagan
- Royal National Orthopaedic Hospital, Stanmore Cancer Institute, University College London, London, UK
| | - H Gelderblom
- Department of Pediatrics and Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - A Goorin
- Dana-Farber Cancer Institute, Boston
| | - R Gorlick
- Section of Pediatric Hematology/Oncology, Montefiore Medical Center, Bronx, USA
| | - G Gosheger
- Department of General Orthopedics and Tumor Orthopedics, University Hospital Muenster, Muenster, Germany
| | - R J Grimer
- Royal Orthopaedic Hospital, Birmingham, UK
| | - K S Hall
- Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway
| | - K Helmke
- Department of Pediatric Radiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P C W Hogendoorn
- Department of Pediatrics and Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - G Jundt
- Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - L Kager
- St Anna Children's Hospital, Vienna, Austria
| | - T Kuehne
- University Children's Hospital Basel, Basel, Switzerland
| | - C C Lau
- Texas Children's Cancer Centre, Baylor College of Medicine, Houston
| | - G D Letson
- H. Lee Moffit Cancer Centre & Research Institute, Tampa
| | - J Meyer
- Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia
| | - P A Meyers
- Memorial Sloan-Kettering Cancer Center, New?York
| | - C Morris
- Memorial Sloan-Kettering Cancer Center, New?York Orthopedic Surgery, Johns Hopkins, Baltimore, USA
| | - H Mottl
- Department of Pediatric Hematology Oncology, University Hospital, Prague, Czech Republic
| | - H Nadel
- British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada
| | - R Nagarajan
- Cincinnati Children's Hospital Medical Center, Cincinnati
| | - R L Randall
- Primary Children's Hospital and Huntsman Cancer Institute, University of Utah, Salt Lake City
| | | | - R Schwarz
- Department of Radiation Oncology, Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L A Teot
- Department of Pathology, Boston Children's Hospital, Boston, USA
| | - M R Sydes
- Medical Research Council Clinical Trials Unit at University College London, London, UK
| | - M Bernstein
- IWK Health Center, Dalhousie University, Halifax, Canada
| | | |
Collapse
|
35
|
Uwineza A, Gill H, Buckley P, Owens C, Capra M, O'Sullivan C, McDermott M, Brett F, Farrell M, Pears J, O'Sullivan MJ. Rhabdoid tumor: the Irish experience 1986–2013. Cancer Genet 2014; 207:398-402. [DOI: 10.1016/j.cancergen.2014.05.015] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/23/2014] [Accepted: 05/31/2014] [Indexed: 12/23/2022]
|
36
|
Nason GJ, Baker JF, Seoighe D, Irvine AD, McDermott M, Orr D, Capra M, Kelly PM. Congenital-infantile fibrosarcoma of the foot--avoidance of amputation. Ir Med J 2014; 107:148-149. [PMID: 24908860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Congenital-infantile fibrosarcoma is a rare entity with a five year survival rate of over 90%. Surgery is still the most common treatment modality with amputation often necessary. There have been reports supporting the use of neoadjuvant chemotherapy to debulk the tumour in an effort to facilitate limb sparing surgery. We report a case of a newborn who presented with a life threatening haemorrhage from a fibrosarcoma of the foot, successfully treated with Vincristine, Actinomycin and Cyclophosphamide (VAC) chemotherapy alone.
Collapse
|
37
|
Higgins E, Capra M, Schwartz M, Smith F, McLean W, Irvine A. Resolution of the plantar hyperkeratosis of pachyonychia congenita during chemotherapy for Ewing sarcoma. Br J Dermatol 2013; 169:1357-60. [DOI: 10.1111/bjd.12574] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- E. Higgins
- Department of Paediatric Dermatology Our Lady's Children's Hospital Crumlin Dublin Ireland
| | - M. Capra
- Department of Oncology Our Lady's Children's Hospital Crumlin Dublin Ireland
| | - M.E. Schwartz
- Pachyonychia Congenita Project Salt Lake City UT U.S.A
| | - F.J.D. Smith
- Centre for Dermatology and Genetic Medicine College of Life Sciences and College of Medicine Dentistry and Nursing University of Dundee Dundee DD1 5EH U.K
| | - W.H.I. McLean
- Centre for Dermatology and Genetic Medicine College of Life Sciences and College of Medicine Dentistry and Nursing University of Dundee Dundee DD1 5EH U.K
| | - A.D. Irvine
- Department of Paediatric Dermatology Our Lady's Children's Hospital Crumlin Dublin Ireland
- National Children's Research Centre Our Lady's Children's Hospital Crumlin Dublin Ireland
- Department of Clinical Medicine Trinity College Dublin Dublin Ireland
| |
Collapse
|
38
|
Perseghin P, Incontri A, Capra M. Erythrocyte-exchange in sickle-cell disease patients. A comparison between Caridian COBE Spectra and Optia cell separators. Transfus Apher Sci 2013; 48:177. [DOI: 10.1016/j.transci.2013.02.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
O'Halloran PJ, Farrell M, Caird J, Capra M, O'Brien D. Paediatric spinal glioblastoma: case report and review of therapeutic strategies. Childs Nerv Syst 2013; 29:367-74. [PMID: 23319103 DOI: 10.1007/s00381-013-2023-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2012] [Accepted: 01/03/2013] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Although uncommon, there is significant morbidity and mortality associated with paediatric spinal glioblastoma. The paucity of cases makes treatment options difficult. The current recommended standard of care is biopsy followed by adjuvant chemo-radiotherapy, with emerging data supporting the role of safe gross total resection. OBJECTIVE The purpose of this paper is to provide a single-institution case study and to discuss current and future therapeutic treatment strategies. CASE PRESENTATION A 14-year-old boy presented with a 2-year history of intermittent back pain with recent progressively worsening motor and sensory deficits of the right side. Pre-operative MRI revealed an enhancing intra-medullary tumour extending from C2 to C7. During the operative case, no tumour-cord margin could be identified, and the patient underwent a subtotal excision. Histopathology confirmed glioblastoma. In the subsequent weeks, the patient's clinical condition deteriorated. Adjuvant therapy was declined by the family, and the patient died 9 weeks after initial presentation. CONCLUSION Despite major advances in surgical techniques, peri-operative neuro-imaging as well as chemo-radiotherapy, the prognosis of a paediatric intra-medullary high-grade spinal tumour remains poor. Detailed analysis of our understanding of tumour dynamics in this patient group is important in establishing future therapeutic strategies.
Collapse
|
40
|
Abstract
We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant “induction” chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily × 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of “maintenance” chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment.
Collapse
Affiliation(s)
- Colin Patrick Hawkes
- Department of Haematology/ Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | | | | | | | | |
Collapse
|
41
|
Abstract
An audit was conducted of the management of chemotherapy-induced nausea and vomiting in children and young people in the national Irish paediatric cancer unit. Over three months, the anti-emetic medication and the incidence of nausea and vomiting in 50 consecutive patient episodes were recorded among 25 children receiving chemotherapy for diverse malignancies. Anti-emetic prescription was found to be unrelated to the emetogenic potential of the chemotherapy received, so that effectiveness varied. Dexamethasone was used in only one case. Twenty children did not take any anti-emetics following discharge, although 11 experienced delayed vomiting, evidence-based guidelines were established and now include anti-emetic prescription that is proportional to the emetogenic potential of the chemotherapeutic regimen. It is also recommended that staff, patients, families and carers should receive education about the need for prescription and use of anti-emetics after discharge.
Collapse
Affiliation(s)
- Frieda Clinton
- Haematology Oncology Unit, Our Lady's Children's Hospital, Dublin, Ireland.
| | | | | |
Collapse
|
42
|
Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall’Igna P, Otte JB, De Camargo B, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P, Perilongo G. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience. Eur J Cancer 2012; 48:1543-9. [DOI: 10.1016/j.ejca.2011.12.011] [Citation(s) in RCA: 127] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2011] [Revised: 11/29/2011] [Accepted: 12/11/2011] [Indexed: 11/29/2022]
|
43
|
Howley S, Stack D, Morris T, McDermott M, Capra M, Betts D, O'Sullivan MJ. Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6. Hum Pathol 2012; 43:299-302. [PMID: 21803398 DOI: 10.1016/j.humpath.2011.03.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Revised: 02/15/2011] [Accepted: 03/11/2011] [Indexed: 12/19/2022]
Abstract
Ectomesenchymoma is a rare mesenchymal malignancy occurring mainly in the pediatric population. The hallmark diagnostic features are a combination of sarcoma, usually rhabdomyosarcoma (RMS) with admixed ganglion cells. The lesion arises either in soft tissues or the cranial cavity, and outcomes vary considerably. Current knowledge about the genetics and biology of ectomesenchymoma is extremely limited with only 4 published karyotypes, showing overlaps only in trisomies 2, 8, and 11. Here, we describe a case with genetic findings that, in conjunction with preexisting observations, offer some additional insights into the genetic aberrations of ectomesenchymoma.
Collapse
Affiliation(s)
- Sinead Howley
- National Children's Research Centre, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| | | | | | | | | | | | | |
Collapse
|
44
|
Gamberini M, Meloni A, Caruso V, Capra M, Cianciulli P, Chiodi E, Lombardi M, Pepe A. Endocrine Effects on Heart Function. Thalassemia Reports 2011. [DOI: 10.4081/thal.2011.s2.e19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Among the factors associated with thalassemic heart disease, endocrine disturbance is also a contributing factor. We present a retrospective, cross sectional study, which aims to establish the prevalence of cardiac complications in thalassaemia major (TM) patients with endocrine complications and to evaluate the influence of endocrine disease on cardiac complications. Endocrinological and cardiological parameters were considered on 957 TM patients who are enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) network in 68 sites in Italy. Patients with pubertal hypogonadism (163 males and 175 females), hypothyroidism (192), diabetes mellitus (87) and hypoparathyroidism (61), were compared according to cardiac complications: global heart T2*, cardiac dysfunction, heart failure, arrythmias, pulmonary hypertension and myocardial fibrosis. Control groups were made up according to the age range of patients with the corresponding endocrinopathy. The prevalence of cardiac dysfunction, arrhythmias and heart failure was significantly increased in patients with endocrinopathies. Cardiac complications tended to increase according to the number of endocrinologies affecting the patient. Aim of our retrospective and cross sectional study was to establish the prevalence of cardiac complications in thalassemia major (TM) patients with endocrine diseases and to evaluate the influence of endocrine diseases on cardiac complications.与地中海贫血心脏疾病相关的因素中,内分泌失调也是一个促进因素。 我们进行了回顾和断面研究,旨在患有内分泌并发症的重型地中海贫血患者中建立心脏并发症的患病率,以及评估内分泌疾病对心脏并发症的影响。 曾考虑到意大利地中海贫血心肌铁过载(MIOT)网络的68个站点上注册的957名重型地中海贫血患者的内分泌和心脏病学参数。 根据以下心脏并发症对青春期性腺机能减退的患者(男性163名、女性175名)、甲状腺机能减退患者(192名)、糖尿病患者(87名)和甲状旁腺机能减退患者(61名)进行了比较: 心脏 T2*、心功能障碍、心脏衰竭、心率不齐、肺动脉高血压以及心肌纤维化。 根据相应内分泌病患者的年龄范围建立了对照组。 心功能障碍、心率不齐和心脏衰竭的患病率在内分泌病患者中明显增加。 根据影响患者的内分泌病的数量,心脏并发症倾向于增加。
Collapse
|
45
|
Curry S, Ibrahim F, Grehan D, McDermott M, Capra M, Betts D, O'Sullivan M. Rhabdomyosarcoma-associated renal cell carcinoma: a link with constitutional Tp53 mutation. Pediatr Dev Pathol 2011; 14:248-51. [PMID: 21054160 DOI: 10.2350/10-07-0871-cr.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The 2004 World Health Organization classification includes the new entity "neuroblastoma-associated renal cell carcinoma." The pathogenetic link between these entities is unknown as yet. The patient reported herein developed renal cell carcinoma after anaplastic embryonal rhabdomyosarcoma, a previously unknown association. The 2nd malignancy developed very soon after the 1st one, prompting concern for inherent cancer predisposition rather than a therapy-induced 2nd malignancy. A variety of features raised suspicion for Tp53 mutation, and indeed a pathogenic germline Tp53 mutation was identified in this child, despite a negative family history for Li-Fraumeni syndrome. Consideration of underlying predisposition is advocated in the context of rapid evolution of 2nd childhood malignancy.
Collapse
Affiliation(s)
- Sarah Curry
- Department of Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | | | | | | | | | | | | |
Collapse
|
46
|
Walsh PM, Byrne J, Capra M, Comber H. Childhood cancer survival in Ireland: temporal, regional and deprivation-related patterns. Eur J Cancer 2011; 47:1852-62. [PMID: 21530237 DOI: 10.1016/j.ejca.2011.03.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2010] [Revised: 02/23/2011] [Accepted: 03/21/2011] [Indexed: 11/26/2022]
Abstract
Survival after childhood cancer varies across Europe, but national or regional studies have so far shown no survival differences related to socio-economic disparity. The relationship of childhood cancer survival to disparity has not been studied in Ireland. We assessed observed survival for Irish children (ages 0-14 years) diagnosed with cancer during the period 1994-2005, overall (for all cancers included in the 3rd edition of the International Classification of Childhood Cancer) and for three main diagnostic groups - leukaemias, lymphomas, and central nervous system tumours. Comparisons were made between two diagnosis periods (1994-1999 and 2000-2005), between four regions of residence, and between five area-based deprivation categories. Regional patterns of treatment were examined to help assess the impact of centralisation of services. There was only limited evidence of improvements in survival over time. No clear evidence was found of deprivation-related influences on childhood cancer survival in Ireland, overall or for the three main diagnostic groups examined, although a weak trend was apparent for lymphoid leukaemias. Regional variation in survival was likewise not clear-cut, with the possible exception of CNS tumours (significantly higher survival amongst patients resident in the Western region). The absence of clear trends or patterns for regional or deprivation-related variation in survival may reflect a high degree of coordination and uniformity of treatment (and perhaps diagnostic) services, and application of standard treatment protocols nationally.
Collapse
Affiliation(s)
- Paul M Walsh
- National Cancer Registry, Building 6800, Cork Airport Business Park, Kinsale Road, Cork, Ireland.
| | | | | | | |
Collapse
|
47
|
Rizkalla H, Wildgrove H, Quinn F, Capra M, O'Sullivan MJ. Congenital fibrosarcoma of the ileum: case report with molecular confirmation and literature review. Fetal Pediatr Pathol 2011; 30:156-60. [PMID: 21355680 DOI: 10.3109/15513815.2010.547554] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Congenital fibrosarcoma is a rare, soft tissue malignancy of infancy, most commonly involving the distal extremities. We report a case of congenital fibrosarcoma of the ileum in a 5-day-old boy who presented with an acute abdomen due to ileal perforation. Partial ileal resection was carried out with successful anastomosis. Grossly, the resected small bowel showed focal luminal stenosis with a thickened, indurated wall. Histology showed a transmural primitive spindle cell proliferation with a morphology consistent with congenital fibrosarcoma. The associated hallmark chromosomal translocation t(12;15)(q13;q25) was demonstrated by reverse transcriptase polymerase chain reaction.
Collapse
Affiliation(s)
- Hala Rizkalla
- Department of Pathology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | | | | | | | | |
Collapse
|
48
|
Affiliation(s)
- Sarah Curry
- Department of Oncology, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland
| | | | | | | | | |
Collapse
|
49
|
Abstract
INTRODUCTION Chemotherapy has limited role in the up-front management of ependymoma. At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience. METHODS The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma. DISCUSSION The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.
Collapse
Affiliation(s)
- Eric Bouffet
- Paediatric Neuro-Oncology Program, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G1X8, Canada.
| | | | | |
Collapse
|
50
|
Gelosa G, Tremolizzo L, Galbussera A, Perego R, Capra M, Frigo M, Apale P, Ferrarese C, Appollonio I. Narrowing the window for ‘senile chorea’: A case with primary antiphospholipid syndrome. J Neurol Sci 2009; 284:211-3. [DOI: 10.1016/j.jns.2009.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Revised: 04/24/2009] [Accepted: 05/07/2009] [Indexed: 11/30/2022]
|